Introduction {#s1}
============

Antibiotics are commonly used in the treatment of bacterial infections, and, in effectively combating such diseases, have substantially increased human life expectancy. As with most drugs, antibiotic treatment can also alter host metabolism, leading to adverse side-effects, including nausea, hepatotoxicity, skin reactions, and gastrointestinal and neurological disorders. Such side-effects can become critical when antibiotic treatment is long and involves several drugs, as in the treatment of tuberculosis (TB), where 2--28% of patients develop mild liver injury during treatment with first-line drugs ([@bib1]).

Antibiotics can interfere with the immune system, indirectly through the disturbance of the body's microbiota ([@bib59]), or directly by modulating the functions of immune cells. Such interactions may impact treatment efficacy or the susceptibility of the host to concomitant infection. For example, after treatment completion, TB patients are more vulnerable to reactivation and reinfection of the disease, suggesting therapy-related immune impairment ([@bib10]). Drug-sensitive TB can be cured by combining up to four antibiotics in a 6-month treatment; specifically, isoniazid (INH), rifampicin (RIF), ethambutol (EMB) and pyrazinamide (PZA) for 2 months, and INH and RIF for additional 4 months. INH induces apoptosis of activated CD4^+^ T cells in *Mycobacterium tuberculosis* (MTB)-infected mice ([@bib56]) and leads to a decrease in Th1 cytokine production in household contacts with latent TB under preventive INH therapy ([@bib7]). RIF has immunomodulatory properties and acts as a mild immunosuppressive agent in psoriasis ([@bib58]). RIF reduces inflammation by inhibiting IκBα degradation, mitogen-activated protein kinase (MAPK) phosphorylation ([@bib5]), and Toll-like receptor 4 signaling ([@bib61]). PZA treatment of MTB-infected human monocytes and mice significantly reduces the release of pro-inflammatory cytokines and chemokines ([@bib34]). Recently, Puyskens et al. showed that several anti-TB drugs bind to the aryl hydrocarbon receptor and may impact host defense ([@bib41]). It is therefore necessary to understand how antibiotic treatment modulates macrophage functions, and more generally, how it impacts the host immune response.

The worldwide rise in antibiotic resistance is a major threat to global health care. A growing number of bacterial infections, such as pneumonia, salmonellosis, and TB, are becoming harder to treat as the antibiotics used to treat them become less effective. While new antibiotics are being developed and brought to the clinic, their effects on the human immune system are not being studied in-depth. Here, we have investigated the impact of a recently approved anti-TB drug, bedaquiline (BDQ), on the transcriptional responses of human macrophages infected with MTB. Macrophages are the primary cell target of MTB, which has evolved several strategies to survive and multiply inside the macrophage phagosome, including prevention of phagosome acidification ([@bib52]), inhibition of phagolysosomal fusion ([@bib3]) and phagosomal rupture ([@bib50]; [@bib60]). They play a central role in the host response to TB pathogenesis, by orchestrating the formation of granulomas, presenting mycobacterial antigens to T cells, and killing the bacillus upon IFN-γ activation ([@bib9]). BDQ is a diarylquinoline that specifically inhibits a subunit of the bacterial adenosine triphosphate (ATP) synthase, decreasing intracellular ATP levels ([@bib2]; [@bib26]). It has 20,000 times less affinity for human ATP synthase ([@bib20]). The most common side effects of BDQ are nausea, joint and chest pain, headache, and arrhythmias ([@bib13]; [@bib55]). However, possible interactions between BDQ and the host immune response have not been studied in detail. Understanding the impact of BDQ on the host immune response may help to develop strategies aiming at improving drug efficacy and limiting side-effects, including cytotoxicity, alteration of cell metabolism, and immunomodulation.

Results {#s2}
=======

BDQ modulates the response of naïve and MTB-infected macrophages {#s2-1}
----------------------------------------------------------------

We treated human monocyte-derived macrophages from four healthy donors with BDQ at 5 µg/mL, which corresponds to the concentration detected in the plasma of TB patients treated with BDQ ([@bib2]). This concentration did not affect cell viability over an incubation period of 7 days ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). After 18 hr of treatment, we characterized the genome-wide gene expression profiles of BDQ-treated macrophages by RNAseq, with DMSO-treated cells serving as a control. The expression of 579 genes was affected by BDQ (FDR \< 0.05, [Figure 1---source datas 1](#fig1sdata1){ref-type="supplementary-material"} and [2](#fig1sdata2){ref-type="supplementary-material"}), with 186 being upregulated and 393 being downregulated. We classified all 579 genes by performing gene-set enrichment analysis using ClueGO cluster analysis ([@bib6]). The gene set upregulated by BDQ was significantly enriched for genes associated with lysosome, phagocytic vesicle membrane, vacuolar lumen, hydrolase activity and lipid homeostasis ([Figure 1A](#fig1){ref-type="fig"}).

![BDQ modulates the response of human macrophages.\
Cells from four individual donors were treated with BDQ (5 μg/mL) for 18 hr. Differentially expressed genes were identified by mRNAseq. (**A**) Gene ontology enrichment analysis of genes whose expression is upregulated by BDQ treatment, using the Cytoscape app ClueGO (FDR \< 0.05; LogFC \>0.5). (**B**) Cells were infected with BDQ-resistant MTB for 24 hr and then treated with BDQ (5 μg/mL) for an additional 18 hr. Gene ontology enrichment analysis of genes whose expression is up-regulated by BDQ treatment in BDQr-MTB-infected cells, using the Cytoscape app ClueGO (FDR \< 0.05; LogFC \>0.5). (**C**) Venn diagram showing the number of genes regulated by BDQ treatment in naive and BDQr-MTB-infected macrophages, relative to untreated controls. (**D**) Heatmap showing differential expression of genes differentially expressed by BDQ in naive and BDQr-MTB-infected cells. Each column corresponds to one donor. Data were normalized to determine the log ratio with respect to the median expression of each gene.\
Figure 1---source data 1.Genes whose expression is upregulated in naive macrophages upon BDQ treatment.FDR \< 0.05.\
Figure 1---source data 2.Genes whose expression is downregulated in naive macrophages upon BDQ treatment.FDR \< 0.05.\
Figure 1---source data 3.Genes whose expression is upregulated in BDQr-MTB-infected macrophages upon BDQ treatment.FDR \< 0.05.\
Figure 1---source data 4.Genes whose expression is downregulated in BDQr-MTB-infected macrophages upon BDQ treatment.FDR \< 0.05.\
Figure 1---source data 5.Genes differentially expressed in BDQr-MTB infected macrophages by BDQ.FDR \< 0.05.\
Figure 1---source data 6.Genes differentially expressed in naive macrophages by BDQ.FDR \< 0.05.\
Figure 1---source data 7.Differentially expressed genes both in naive and in BDQr-MTB infected macrophages upon BDQ treatment.FDR \< 0.05.](elife-55692-fig1){#fig1}

###### Gene Ontology (GO) functional annotation of genes differentially expressed by BDQ only in naïve- and BDQr-MTB-infected macrophages.

  Specific NAIVE BDQ genes                                                                  
  -------------------------------------------------------- ------------ ---------- -- -- -- --
  GO category                                              avg. LogFC   p-value             
  Cell division                                            -0.51        8.34E-05            
  Sphingolipid metabolic process                           0.33         1.42E-04            
  Angiogenesis                                             0.67         5.16E-04            
  Spindle                                                  -0.63        5.46E-04            
  Lysosomal lumen                                          0.35         1.21E-04            
  Glycosphingolipid metabolic process                      0.35         1.21E-03            
  Response to oxidative stress                             0.49         1.26E-03            
  Mitotic cell cycle                                       -0.58        1.29E-03            
  **Specific INFECTED BDQ genes**                                                           
  GO category                                              avg. LogFC   p-value             
  Endoplasmatic reticulum-Golgi intermediate compartment   -0.38        2.90E-07            
  Membrane raft                                            -0.34        4.93E-05            
  Cellular protein metabolic process                       -0.35        3.32E-04            
  Lipid binding                                            -0.36        4.88E-04            
  Ribonucleoprotein complex binding                        -0.37        5.17E-04            
  Protein dephosphorylation                                -0.34        5.43E-04            
  Lysosomal membrane                                       -0.34        6.31E-04            
  Ubiquitin-dependent protein catabolic process            0.74         6.48E-04            
                                                                                            

We next evaluated if BDQ could modulate gene expression in MTB-infected cells. In order to exclude potential differences due to the MTB bacillary load between treated and untreated cells, we generated a virulent BDQ-resistant strain of *M. tuberculosis* (BDQr-MTB). The selected clone, which carried a Ala63→Pro mutation in subunit c of the ATP synthase ([@bib2]; [Figure 1---figure supplement 2A](#fig1s2){ref-type="fig"}), had a similar generation time to wild-type bacteria when cultured in 7H9 liquid medium, although we observed a slower growth after 7 days of treatment. ([Figure 1---figure supplement 2B](#fig1s2){ref-type="fig"}). We also noted no difference in virulence or in intracellular growth of both wild-type- and BDQ-resistant MTB ([Figure 1---figure supplement 2C-E](#fig1s2){ref-type="fig"}). As expected, the MIC~99~ (defined as the concentration required to prevent 99% growth) for susceptible MTB was 0.07 µg/mL, a value similar to previously published study ([@bib2]), while the MIC~99~ of the BDQr-MTB was 36 µg/mL. We infected macrophages with BDQr-MTB. After 24 hr of infection, cells were incubated for an additional 18 hr with BDQ (5 µg/mL). The bacillary load of resistant MTB inside macrophages was the same in untreated cells as in cells after 18 hr of BDQ treatment. In contrast, in the same experiment using BDQ-susceptible MTB, there was a 70% decrease in the bacillary load ([Figure 1---figure supplement 2C](#fig1s2){ref-type="fig"}).

Following treatment, we characterized the genome-wide gene expression profiles of MTB-infected macrophages, as described above. The expression of 1,495 genes was affected by BDQ (FDR \< 0.05, [Figure 1A](#fig1){ref-type="fig"}, [Figure 1---source datas 3](#fig1sdata3){ref-type="supplementary-material"} and [4](#fig1sdata4){ref-type="supplementary-material"}), with 499 being upregulated and 996 being downregulated. More genes were thus affected by BDQ treatment in MTB-infected cells than in naive macrophages. This probably reflects the fact that MTB infection induces an extensive remodeling of the transcriptome ([@bib4]; [@bib54]). The genes differentially expressed by BDQ only in MTB-infected macrophages are enriched in genes related to assembly of the endoplasmic reticulum-Golgi intermediate compartment, membrane raft and cellular protein metabolic process ([Table 1](#table1){ref-type="table"}, [Figure 1---source datas 5](#fig1sdata5){ref-type="supplementary-material"} and [6](#fig1sdata6){ref-type="supplementary-material"}). This probably reflects the cell adaptation to infection. Functional annotation of the gene set upregulated by BDQ also revealed that similar pathways were affected by BDQ in naive and BDQr-MTB-infected macrophages, with an enrichment for genes associated with glucose/phospholipid metabolism and lysosome ([Figure 1B](#fig1){ref-type="fig"}, [Figure 1---source datas 3](#fig1sdata3){ref-type="supplementary-material"} and [4](#fig1sdata4){ref-type="supplementary-material"}). 452 genes were differentially expressed in both naive and MTB-infected cells upon BDQ treatment with an over-representation of lysosome-associated genes ([Figure 1C--D](#fig1){ref-type="fig"}, [Figure 1---source data 7](#fig1sdata7){ref-type="supplementary-material"}).

BDQ affects host metabolism {#s2-2}
---------------------------

As metabolic pathways were over-represented in our RNAseq analysis, we investigated if glycolysis is affected by BDQ treatment using the Seahorse Extracellular Flux analyzer. This assay measures the rate of proton accumulation in the extracellular medium during glycolysis (glycoPER) and can discriminate between basal glycolysis, induced glycolytic capacity (by addition of rotenone/antimycin A (Rot/AA), an inhibitor of the mitochondrial electron transport chain), and non-glycolytic acidification (by addition of the glycolytic inhibitor 2-deoxy-D-glycose (2-DG)). After incubation with BDQ, we observed a 30% decrease in basal glycolysis and glycolytic capacity compared to untreated cells ([Figure 2A--B](#fig2){ref-type="fig"}, [Figure 2---figure supplement 1A--B](#fig2s1){ref-type="fig"}).

![Modulation of host metabolism by BDQ.\
(**A--B**) The Glycolytic Rate Assay was performed in heat killed-MTB stimulated macrophages treated with BDQ, in the presence of rotenone/antimycin A (Rot/AA) and 2-deoxy-D-glycose (2-DG), inhibitors of the mitochondrial electron transport chain and glycolysis, respectively (one-way ANOVA test). One representative experiment (of two) is shown. (**C**) Lipid profile of BDQr-MTB infected cells treated with BDQ, by MALDI-TOF (unpaired two tailed Student's t test). PI: Phosphotidylinositol; CL: Cardiolipids; PE: Phosphatidylethanolamine; PG: Phosphatidylglycerol. Numbers correspond to mass-to-charge ratio (m/z). Cells derived from three donors were analyzed. Error bars represent the mean ± SD and significant differences between treatments are indicated by an asterisk, in which \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001.](elife-55692-fig2){#fig2}

We assessed phospholipid metabolism, a pathway also identified in our ClueGO cluster analysis ([Figure 1B](#fig1){ref-type="fig"}). Like glycolysis, lipid metabolism affects macrophage phenotype and function ([@bib43]). We analyzed the lipid profile of BDQ-treated cells using MALDI-TOF mass spectrometry. We observed an increase of phosphatidylinositols upon incubation with BDQ ([Figure 2C](#fig2){ref-type="fig"}, [Figure 2---figure supplement 1C](#fig2s1){ref-type="fig"}). No significant changes were observed in the levels of phosphatidylethanolamines, phosphatidylglycerols, or cardiolipins. Taken together, these data show that BDQ induced a significant metabolic reprogramming of both MTB-infected and resting macrophages.

BDQ increases macrophage lysosomal activity {#s2-3}
-------------------------------------------

Macrophages are involved in innate immunity and tissue homeostasis through their detection and elimination of microbes, debris, and dead cells, which occurs in lysosomes ([@bib64]). Lysosomes are acidic and hydrolytic organelles responsible for the digestion of macromolecules. Recent work has shown that they are also signaling platforms, which respond to nutrient and cellular stress ([@bib28]). Functional annotations based on the GO database of the differentially expressed genes suggested a substantial impact of BDQ treatment on lysosome function ([Figure 1A--B](#fig1){ref-type="fig"}). We identified 38 and 54 differentially expressed genes by BDQ, respectively in naïve- and BDQr-MTB infected cells (FDR \< 0.05, [Figure 3A](#fig3){ref-type="fig"}). These genes are involved in lysosome biogenesis, transport and degradation of small molecules, and lysosomal acidification. They included genes coding for components of vacuolar ATPase (V-ATPase), hydrolases, and SLC11A1 (NRAMP1), a divalent transition metal transporter involved in host resistance to pathogens, including MTB ([@bib36]).

![BDQ activates the lysosomal pathway in human MTB-infected macrophages.\
(**A**) Heatmap showing differential expression of genes included in the Lysosome KEGG category (p-value\<0.05). Each column corresponds to one donor. Data were normalized to determine the log ratio with respect to the median expression of each gene. (**B**) Macrophages were infected with BDQr-MTB expressing the GFP protein and incubated with BDQ (5 μg/mL) for 3 hr, 18 hr and 48 hr. Acid organelles were then labeled with 100 nM LysoTracker DND-99 for 1 hr. The fluorescence intensity was quantified by flow cytometry. (**C--E**) Cells were infected with GFP expressing BDQr-MTB (green) and treated with BDQ (5 μg/mL). After 18 hr and 48 hr of treatment, cells were labelled with LysoTracker (red) and fluorescence was analyzed by confocal microscopy. DAPI (blue) was used to visualize nuclei (scale bar: 10 μm). The quantification of LysoTracker staining and the percentage of LysoTracker-positive MTB phagosomes were performed using Icy software. (**F**) Macrophages were activated with heat-killed MTB and treated with BDQ for 18 hr and 48 hr. Cells were then incubated with DQ-Green BSA. Fluorescence was quantified by flow cytometry. Significant differences between BDQ treatment and control (DMSO) are indicated by an asterisk. One representative experiment (of at least three) is shown. Error bars represent the mean ± SD. \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001.](elife-55692-fig3){#fig3}

To validate our transcriptomic data, we incubated BDQ-treated, BDQr-MTB-infected cells with LysoTracker Red DND-99, a red fluorescent probe that labels acidic organelles, and analyzed them using flow cytometry. No differences were observed between control and treatment after 3 hr of BDQ treatment ([Figure 3B](#fig3){ref-type="fig"}). However, at 18 hr and 48 hr post-treatment, fluorescence intensity was substantially increased in macrophages incubated with BDQ compared to DMSO-treated cells (1.7 and 5.4 times more, respectively). These results were supported by confocal microscopy, which revealed the appearance of numerous acidic compartments upon treatment ([Figure 3C](#fig3){ref-type="fig"}), up to five times more in BDQ-treated macrophages than untreated cells at 48 hr post-treatment (p\<0.001, [Figure 3D](#fig3){ref-type="fig"}). We also observed a large number of MTB phagosomes co-localized with LysoTracker-positive compartments ([Figure 3E](#fig3){ref-type="fig"}). As the expression of many genes coding for hydrolases was upregulated upon BDQ treatment ([Figure 3A](#fig3){ref-type="fig"}), we tested the effect of the drug on late endosomal/lysosomal proteolytic activity. BDQ-treated macrophages were incubated with DQ-Green BSA, a self-quenched non-fluorescent probe that produces brightly fluorescent peptides following hydrolysis by lysosomal proteases. At 18 hr and 48 hr post-treatment, we observed a dose-dependent increase in fluorescence intensity upon treatment with BDQ (up to 5.5 times more than untreated cells, p\<0.01, [Figure 3F](#fig3){ref-type="fig"}). Similar results were obtained when we incubated naive macrophages with BDQ ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). Together, these data demonstrate that BDQ induces biogenesis of competent lysosomes.

We performed additional experiments to confirm that the main effects of BDQ on lysosome were independent of infection with live bacteria. Briefly, cells were untreated or stimulated with LPS (TLR4 agonist), Pam3CSK4 (TLR1/2 agonist), heat-killed bacteria (hk-MTB), drug-susceptible MTB or BDQr-MTB, and treated with BDQ. After 18 hr, RNA was collected and we performed RT-qPCR on a panel of lysosomal genes. We also analyzed the intensity of the LysoTracker staining using flow cytometry ([Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}). Our results clearly show that the main effects on lysosome biogenesis/activation occurred with BDQ treatment and were not exclusively seen after infection with live MTB.

BDQ potentiates PZA antimycobacterial activity {#s2-4}
----------------------------------------------

The capacity of BDQ to induce acidic compartments may potentiate the efficacy of other drugs, whose activity is pH dependent. In vivo studies have suggested a synergistic interaction between BDQ and PZA ([@bib22]), and it is commonly assumed that a low pH is required for PZA activity against MTB ([@bib69]). We thus infected macrophages with BDQr-MTB and treated them with BDQ and PZA. After 7 days of treatment, cells were lysed and bacteria counted. PZA showed moderate bactericidal activity, with 50 µg/mL PZA resulting in a 36% decrease in bacterial numbers compared to untreated cells ([Figure 4A](#fig4){ref-type="fig"}). We confirmed that the combination of PZA with BDQ was highly bactericidal on MTB, leading to a 83% decrease in colony forming units using 50 µg/mL PZA. This decrease was not a result of an additive effect between the two drugs, as BDQ alone at 1 µg/mL had no antibacterial activity. We also found no synergy between BDQ and PZA on the BDQ-resistant mutant cultivated in Middlebrook 7H9 liquid medium ([Figure 4B](#fig4){ref-type="fig"}). Thus, the potentiation of PZA activity by BDQ is most likely due to the effect of BDQ on the host cell, and in particular on the increase of lysosomal acidification.

![BDQ potentiates PZA antimycobacterial activity.\
(**A**) Macrophages were infected with BDQr-MTB and treated with BDQ (1 μg/mL) and PZA. After 7 of days treatment, cells were lysed and bacteria were enumerated by CFU (counted in triplicate). (**B**) Optical density (OD) measurements of bacterial growth of BDQr-MTB in the presence of BDQ (1 μg/mL) and different concentrations of PZA. Bacteria were cultured in 7H9 medium supplemented with 10% OADC enrichment with/without the drugs. One representative experiment (of at least three) is shown. Error bars represent the mean ± SD. \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001.](elife-55692-fig4){#fig4}

We next tested whether BDQ would synergize with the other first-line anti-TB drugs in liquid culture or in BDQr-MTB-infected macrophages. We found that BDQ did not potentiate the activity of ethambutol (EMB), isoniazid (INH) and rifampicin (RIF) in either case. While we cannot exclude the possibility that BDQ may have additive effects with other anti-TB drugs, as has been described ([@bib22]), we saw no evidence of synergism with any of the first-line agents ([Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}).

Classical anti-TB drugs did not activate the lysosomal pathway in human macrophages {#s2-5}
-----------------------------------------------------------------------------------

Bacterial hydroxyl radical released after treatment with INH or PZA can directly induce host cell autophagy ([@bib25]). We thus tested whether other antibiotics might have similar effects to BDQ. We characterize the genome-wide gene expression profiles of naïve macrophages and macrophages stimulated with hk-MTB, and treated with amikacin (AMK), EMB, INH, PZA or RIF for 18 hr. We chose drug concentrations based on the concentrations detected in the plasma of treated TB patients. Following treatment, only RIF and PZA significantly modulate gene expression in macrophages. 556 and 752 genes were differentially expressed in cells stimulated with heat-killed bacteria and exposed to RIF and PZA, respectively ([Figure 5A](#fig5){ref-type="fig"}, [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}, [Figure 5---source datas 1](#fig5sdata1){ref-type="supplementary-material"}--[5](#fig5sdata5){ref-type="supplementary-material"}). We classified these genes by performing gene-set enrichment analysis and confirmed that the lysosomal pathway was not induced upon RIF or PZA treatment ([Table 2](#table2){ref-type="table"}). The expression of only two genes belonging to this pathway was upregulated by RIF, and only one by PZA, compared to 46 whose expression was modulated by BDQ ([Figure 5B--C](#fig5){ref-type="fig"}). Consistent with these results, none of these antibiotics were able to increase LysoTracker staining ([Figure 5D](#fig5){ref-type="fig"}).

![Classical anti-TB drugs did not activate the lysosomal pathway in human macrophages.\
(**A**) Number of differentially-expressed genes upon treatment with commonly used anti-TB drugs relative to untreated control. Briefly, naïve- and hk-MTB-stimulated macrophages were treated with AMK (20 µg/mL), EMB (20 µg/mL), INH (10 µg/mL), PZA (200 µg/mL) or RIF (20 µg/mL). After 18 hr, differentially expressed (DE) genes were identified by mRNAseq. (**B--C**) Venn diagram showing the number of genes regulated by PZA and RIF in naive and hk-MTB-stimulated macrophages, in comparison with the number of lysosomal genes differentially expressed by BDQ (FDR \< 0.05, absLogFC \>0.1). (**D**) Macrophages were incubated for 48 hr with AMK, BDQ, EMB, INH, PZA or RIF, and then stained with Lysotracker. Fluorescence intensity was analyzed by flow cytometry. One representative experiment (of at least three) is shown. Error bars represent the mean ± SD. \*p\<0.05.\
Figure 5---source data 1.Differentially expressed genes in hk-MTB stimulated macrophages upon EMB treatment.FDR \< 0.05.\
Figure 5---source data 2.Differentially expressed genes in hk-MTB stimulated macrophages upon RIF treatment.FDR \< 0.05.\
Figure 5---source data 3.Differentially expressed genes in naive macrophages upon RIF treatment.FDR \< 0.05.\
Figure 5---source data 4.Differentially expressed genes in hk-MTB stimulated macrophages upon PZA treatment.FDR \< 0.05.\
Figure 5---source data 5.Regulated genes naive macrophages upon PZA treatment.FDR \< 0.05.](elife-55692-fig5){#fig5}

###### Gene Ontology (GO) functional annotation of differentially expressed genes in naïve- or hk-MTB-stimulated cells treated with PZA or RIF.

  hk-MTB + PZA                                                                                  
  ------------------------------------------------------------ ------------ ---------- -- -- -- --
  GO category                                                  avg. LogFC   p-value             
  Integral to lumenal side of endoplasmic reticulum membrane   0.16         2.79E-04            
  Cytokine-mediated signaling pathway                          0.27         3.28E-04            
  Interferon-gamma-mediated signaling pathway                  0.21         3.56E-04            
  MHC class I receptor activity                                0.16         7.82E-04            
  Cytosolic small ribosomal subunit                            0.26         7.98E-03            
  MHC class I protein complex                                  0.16         1.04E-03            
  Regulation of immune response                                0.22         1.33E-03            
  Negative regulation of MAPK cascade                          0.20         1.34E-03            
  **Naïve + RIF**                                                                               
  GO category                                                  avg. LogFC   p-value             
  Mitotic cell cycle                                           -0.37        1.53E-17            
  DNA replication                                              -0.34        2.59E-13            
  Cell cycle checkpoint                                        -0.36        4.98E-10            
  S phase of mitotic cell cycle                                -0.32        6.29E-10            
  DNA strand elongation involved in DNA replication            -0.33        1.88E-09            
  G1/S transition of mitotic cell cycle                        -0.36        2.02E-09            
  Cell division                                                -0.34        3.96E-09            
  Cell cycle                                                   -0.32        2.26E-07            
  **hk-MTB + RIF**                                                                              
  GO category                                                  avg. LogFC   p-value             
  Melanosome                                                   0.26         4.09E-07            
  Endoplasmic reticulum unfolded protein response              0.29         7.95E-07            
  Electron carrier activity                                    0.23         9.11E-07            
  Tissue regeneration                                          -0.23        1.63E-05            
  Response to drug                                             -0.29        2.32E-05            
  NADP binding                                                 0.22         3.07E-05            
  Cellular lipid metabolic process                             -0.19        4.05E-05            
  Lipid metabolic process                                      -0.23        4.98E-05            
                                                                                                

BDQ induces autophagy activation in macrophages {#s2-6}
-----------------------------------------------

Given BDQ's effect on lysosomal acidification we asked whether it promoted lysosome formation. Lysosome biogenesis is linked to the endocytic and autophagic pathways. Autophagy delivers cytoplasmic material and organelles for lysosomal degradation and is implicated in the immune response to microbes ([@bib17]). We therefore tested three inhibitors of the autophagy pathway on BDQ activity: bafilomycin (BAF), which inhibits the V-ATPase; chloroquine (CQ), a lysomotropic agent which prevents endosomal acidification and impairs autophagosome fusion with lysosomes; and 3-methyladenine (3-MA) which blocks autophagosome formation by inhibiting of the type III phosphatidylinositol 3-kinases (PI-3K). We infected macrophages with BDQr-MTB and incubated the cells with BDQ in the presence or absence of the different inhibitors. These molecules were not toxic at the concentrations tested ([Figure 1---figure supplement 1B](#fig1s1){ref-type="fig"}). After 2 days, we analyzed LysoTracker staining as a read-out of lysosome activation using flow cytometry and observed that all three inhibitors prevented the increase in staining upon BDQ treatment ([Figure 6A](#fig6){ref-type="fig"}).

![BDQ induced autophagy in MTB-infected macrophages.\
(**A**) BDQr-MTB-infected macrophages were incubated with BDQ (5 μg/mL) and different inhibitors of autophagy; bafilomycin (BAF, 100 nM), chloroquine (CQ, 40 μM) and 3-methyladenine (3-MA, 5 mM). After 48 hr, acidic compartments were stained with LysoTracker and fluorescence quantified by flow cytometry. (**B**) Detection by indirect immunofluorescence of LC3 (red) in BDQr-MTB (green) infected macrophages, treated with BDQ for 18 hr and 48 hr (scale bar: 10 μm). DAPI (blue) was used to visualize nuclei. (**C**) Determination of the number of LC3-positive puncta per cell (one-way ANOVA test). (**D**) Western blot analysis of LC3, p62, and α/ß-tubulin in MTB-infected cells treated with BDQ and BAF. (**E**) Densitometric quantification of p62 staining. (**F**) BDQr-MTB-infected macrophages were left untreated or incubated with BDQ, 3-methyladenine (3-MA) and/or bafilomycin (BAF). After 48 hr, the number of intracellular bacteria was enumerated. One representative experiment (of three) is shown. Error bars represent the mean ± SD. \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001.](elife-55692-fig6){#fig6}

Microtubule-associated protein light-chain 3B (LC3B) is involved in the formation of autophagosomes and autolysosomes. We observed an increase of LC3B puncta per cell at 18 hr and 48 hr post-BDQ treatment using confocal microscopy ([Figure 6B--C](#fig6){ref-type="fig"}), which was associated with the detection of lipidated LC3 (LC3-II), the form of LC3 recruited to autophagosomal membranes, and with a decrease in sequestosome 1 (SQSTM1) or p62 levels ([Figure 6D--E](#fig6){ref-type="fig"}). p62 is a ubiquitin-binding scaffold protein, which is degraded upon autophagy induction, and which is used as a marker of autophagic flux ([@bib30]). Given we have previously observed that some mycobacterial phagosomes colocalized with lysosomes in BDQ-treated cells ([Figure 3E](#fig3){ref-type="fig"}), we tested whether BDQ promotes MTB killing, independently of its bactericidal activity on MTB by autophagy. BDQ significantly reduced the number of bacteria (measured by CFU) in cells infected with BDQ-resistant MTB. This effect was completely inhibited by the autophagy inhibitors 3-MA and BAF ([Figure 6F](#fig6){ref-type="fig"}). Overall, these data show BDQ activates the autophagy pathway in human macrophages and this is involved in its anti-TB activity.

BDQ activates macrophage bactericidal functions {#s2-7}
-----------------------------------------------

Autophagy plays numerous roles in innate immunity and in host defenses against intracellular pathogens, including MTB ([@bib19]). We thus asked if BDQ conferred protection to bacterial infections naturally resistant to BDQ. To test this hypothesis, we infected macrophages with two different bacterial species: a gram-positive bacterium, *Staphylococcus aureus* and a gram-negative bacterium, *Salmonella* Typhimurium. We confirmed that these two species are resistant to BDQ, even when exposed to high concentration of the drug (20 µg/mL, [Figure 7A](#fig7){ref-type="fig"}). However, when macrophages were incubated with BDQ and then infected with *S. aureus* and *S.* Typhimurium for 24 hr, we observed a substantial decrease in bacterial survival rates ([Figure 7B](#fig7){ref-type="fig"}).

![BDQ increases macrophage bactericidal functions.\
(**A**) Growth of *S.* Typhimurium and *S. aureus* in liquid medium in the presence of BDQ (20 μg/mL). (**B**) Macrophages were incubated with BDQ and then infected with *S.* Typhimurium or *S. aureus*. The number of intracellular bacteria was enumerated at 24 hr post-infection. (**C**) BDQ-treated macrophages were incubated with 3-MA and then infected with *S. aureus*. The number of bacteria was counted as previously. (**D**) Quantification of NO2- in the supernatant of macrophages incubated with BDQ for 18 hr and 48 hr. (**E**) Cells were treated as in (**C**), 3-MA was replaced by L-NAME (0.1 mM), an inhibitor of nitric oxide (NO) synthesis. One representative experiment (of three) is shown. Error bars represent the mean ± SD. Unpaired two-tailed Student's t test was used. \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001.](elife-55692-fig7){#fig7}

To determine if autophagy is involved in this antibacterial activity, we incubated the infected cells with the autophagy inhibitor, 3-MA, and were unable to revert the macrophage resistance to *S. aureus* infection upon BDQ treatment ([Figure 7C](#fig7){ref-type="fig"}). Macrophages are professional phagocytes, which have evolved a myriad of defense strategies to contain and eradicate bacteria, such as radical formation, phagosome maturation, and metal accumulation ([@bib63]). Upon incubation with BDQ, we detected an increase in the amount of NO2-, a stable derivative of NO, in the culture supernatant of macrophages ([Figure 7D](#fig7){ref-type="fig"}). When the cells were treated with N(G)-nitro-L-arginine methyl ester (L-NAME), an inhibitor of nitric oxide (NO) synthesis, *S. aureus*-infected cells were unable to effectively control infection upon incubation with BDQ ([Figure 7E](#fig7){ref-type="fig"}). Thus, our results suggest that BDQ confers innate resistance to bacterial infection through different mechanisms.

Mitochondrial functions are not affected by BDQ {#s2-8}
-----------------------------------------------

BDQ affects cardiac electrophysiology by prolonging the QT interval ([@bib55]) and it has been suggested that BDQ inhibits the cardiac potassium channel protein encoded by the human ether-a-go-go-related gene (*hERG*) ([@bib23]). Therefore, to further understand the molecular mechanisms underpinning macrophage activation by BDQ, we determined if human monocyte-derived macrophages expressed hERG, but were unable to detect *hERG* RNA by RT-qPCR ([Figure 8---figure supplement 1](#fig8s1){ref-type="fig"}).

We investigated if BDQ might interfere with other activities of mitochondria. Conflicting reports suggest that BDQ inhibits the mitochondrial ATPase ([@bib16]; [@bib20]). We have already shown that there were no significant differences in the amount of cardiolipin, a constituent of inner mitochondrial membranes, between BDQ-treated cells and control cells ([Figure 2C](#fig2){ref-type="fig"}). We quantified changes in mitochondrial membrane potential using flow cytometry in cells incubated with BDQ or with oligomycin, a positive control, which hyperpolarizes the mitochondrial membrane potential, and stained with TMRM. TMRM is a fluorescent cell-permeant dye that accumulates in active mitochondria with intact membrane potentials. No changes were observed when macrophages were incubated with the BDQ for 6, 24 and 48 hr ([Figure 8A](#fig8){ref-type="fig"}). We obtained similar results when mitochondria were stained with MitoTracker Red FM whose accumulation in mitochondria is dependent upon membrane potential ([Figure 8B](#fig8){ref-type="fig"}). We also measured the oxygen consumption rate (OCR), and detected no change in basal respiration, ATP-linked respiration, maximal respiration, and non-mitochondrial respiration in cells treated with BDQ for 24 hr and 48 hr as compared to untreated cells ([Figure 8C](#fig8){ref-type="fig"}, [Figure 8---figure supplement 2](#fig8s2){ref-type="fig"}).

![BDQ does not affect mitochondrial functions.\
(**A**) Macrophages were treated with BDQ for 6, 24 and 48 hr and incubated with TMRM. Fluorescence was quantified by flow cytometry. Oligomycin (OM) is a positive control. (**B**) Cells were treated as in (**A**), and mitochondria were stained with MitoTracker Red FM. The graph represents the ratio between the mean fluorescence intensity of BDQ-treated cells and DMSO-treated cells. (**C**) Oxygen consumption rate (OCR) measured by Seahorse extracellular flux assay of cells incubated with BDQ for 24 hr. Basal respiration, ATP production, maximal respiration, respiratory reserve, and nonmitochondrial respiration were followed by sequential additions of oligomycin (OM, an inhibitor of the ATPase), the mitochondrial oxidative phosphorylation uncoupler FCCP, and the inhibitors of electron transport rotenone/antimycin A (Rot/AA). Error bars represent the mean ± SD of three technical replicates. One representative experiment (of two) is shown. (**D**) At each indicated time points, mitochondrial superoxide (mROS) were stained using the MitoSOX dye in BDQ-treated cells. Antimycin A (AA) is used as a positive control. (**E**) Cells were incubated with BDQ in the presence or not of two antioxidants, glutathione (GSH) and its precursor N-Acetyl-L-cysteine (NAC). After 24 hr, the cells were infected with *S. aureus* for an additional 24 hr. Macrophages were lysed and the number of intracellular bacteria enumerated. One representative experiment (of three) is shown. Error bars represent the mean ± SD. was used. \*\*\*p\<0.001.](elife-55692-fig8){#fig8}

Mitochondrial reactive oxygen species (ROS) are involved in the regulation of several physiological and pathological processes, including autophagy ([@bib45]). We thus stained for mitochondrial superoxide using the MitoSOX dye in BDQ-stimulated cells. Again, we saw no difference upon antibiotic treatment ([Figure 8D](#fig8){ref-type="fig"}). Incubation with the antioxidant glutathione (GSH) or with its precursor N-Acetyl cysteine (NAC), which prevent the formation of mitochondrial ROS and reactive nitrogen species (RNS), did not prevent lysosome activation and the killing of *S. aureus* by BDQ ([Figure 8E](#fig8){ref-type="fig"}). Based on these results, it is unlikely that BDQ alters mitochondrial function in human macrophages.

BDQ regulates lysosome activation through TFEB and calcium signaling {#s2-9}
--------------------------------------------------------------------

Given that BDQ induced a lysosomal gene expression signature in macrophages, we wondered whether BDQ could activate the basic helix-loop-helix transcription factor EB (TFEB). TFEB is a master regulator of autophagy and lysosome biogenesis ([@bib46]). In resting cells, TFEB is largely cytosolic and inactive, but upon activation, it translocates into the nucleus and activates the transcription of many autophagy and lysosomal genes ([@bib46]). We therefore analyzed the cellular localization of TFEB, using confocal microscopy. At 18 hr post-treatment, TFEB was mainly localized in the nucleus of BDQ-treated cells ([Figure 9A--B](#fig9){ref-type="fig"}). The activity of TFEB is regulated by phosphorylation on specific amino acid residues, and its activation is mediated by calcineurin, an endogenous serine/threonine phosphatase, through Ca^2+^ release from the lysosome ([@bib35]). In agreement with these studies, we observed an increase in intracellular Ca^2+^ concentration in macrophages treated for 18 hr with BDQ ([Figure 9C](#fig9){ref-type="fig"}), and confirmed that this intracellular calcium accumulation was required for antibiotic-induced TFEB translocation to the nucleus and lysosomal gene expression. Upon treatment with BAPTA-AM, a cell permeable Ca^2+^ chelator, TFEB remained localized in the cytoplasm of BDQ-treated cells ([Figure 9D](#fig9){ref-type="fig"}), and we were unable to detect changes in the expression of a panel of lysosomal genes, previously identified as differentially expressed in macrophages incubated with BDQ ([Figure 9E](#fig9){ref-type="fig"}). The increased bactericidal activity against *S. aureus* was also abrogated in the presence of BAPTA-AM ([Figure 9F](#fig9){ref-type="fig"}).

![Activation of TFEB by BDQ.\
(**A**) Representative fluorescence microscopy images of macrophages treated with BDQ for 6 hr and 18 hr, or incubated in HBSS for 1 hr (starvation). Cells were stained with antibody against TFEB (red). DAPI (white) was used to visualize nuclei. Scale bar: 10 μm. (**B**) Ratio between nuclear and cytosolic TFEB fluorescence intensity (n \> 100 cells per condition, two-way ANOVA test). (**C**) Macrophages were treated with BDQ for 18 hr and loaded with the fluorescent calcium binding dye Fluo-8 AM. After 1 hr of incubation, Ca2+ concentration was monitored by FLUOstar Omega. (**D**) Ratio between nuclear and cytosolic TFEB fluorescence intensity in starved cells and in cells treated with BDQ and/or with the intracellular calcium chelator BAPTA-AM (n \> 100 cells per condition, two-way ANOVA test). (**E**) Relative gene expression measured by RT-qPCR for a panel of differentially expressed lysosomal genes. BDQ-treated macrophages were either left untreated or incubated with BAPTA-AM. Relative expression levels were normalized to the *rpl24* gene. (**F**) Macrophages were treated with BDQ with or without BAPTA-AM, and then infected with *S. aureus*. After 1 day, cells were lysed and the number of intracellular bacterial colonies was counted (unpaired two tailed Student's t test). (**G**) TFEB expression was inhibited in macrophages using siRNA-mediated gene silencing. Cells were then treated with BDQ. After 48 hr of treatment, Lysotracker staining was quantified by flow cytometry. (**H**) Relative gene expression measured by RT-qPCR for a panel of lysosomal genes in TFEB-silenced cells. Relative expression levels were normalized to the *rpl24* gene. (**I**) TFEB-silenced macrophages were treated with BDQ and infected with *S. aureus*. After 1 day, the cells were lysed and the number of intracellular bacterial colonies was counted. (**J**) TFEB-silenced macrophages were treated with BDQ and infected with BDQr-MTB. After 48 hr, the number of bacteria was counted. Error bars represent the mean ± SD. was used. \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001.](elife-55692-fig9){#fig9}

To study the role of TFEB in the enhancement of bactericidal activity upon BDQ treatment in more depth, we inactivated TFEB expression in human macrophages using siRNA-mediated gene silencing ([@bib57]). The level of TFEB expression was decreased by about 85% upon silencing ([Figure 9---figure supplement 1A](#fig9s1){ref-type="fig"}). After treating the cells with BDQ, we analyzed the intensity of the LysoTracker staining using flow cytometry and performed RT-qPCR on a panel of lysosomal genes. In TFEB-silenced cells, BDQ increases slightly the LysoTracker staining ([Figure 9G](#fig9){ref-type="fig"}), and the expression of *atp6v0a1*, *mcoln1, scarb1 or trpm2* ([Figure 9H](#fig9){ref-type="fig"}). We also infected macrophages with *S. aureus* and MTB, and showed that that TFEB activation is required for better control of both pathogens upon BDQ treatment ([Figure 9I--J](#fig9){ref-type="fig"}). We next evaluated the recruitment of TFEB to the promoters of some lysosomal genes. As expected, BDQ induces the recruitment of TFEB to these promoters ([Figure 9---figure supplement 1B](#fig9s1){ref-type="fig"}). Collectively, our data indicate that BDQ activates TFEB in macrophages and in this way modulates innate immune resistance to bacterial infection.

Discussion {#s3}
==========

The emergence of bacterial strains resistant to antibiotics requires the constant development of new antibiotics, which, beyond their bactericidal activity, may have a significant impact on cellular functions. Here, we have analyzed the effects of the new anti-TB drug BDQ on human macrophages. We found that in addition to its antibacterial activity, BDQ induces cell reprogramming, increasing macrophage bactericidal activity. Gene expression profiling revealed that 1495 genes were differentially expressed in MTB-infected macrophages incubated with BDQ, with over-representation of genes involved in metabolism, lysosome biogenesis, and acidification. Recent work has highlighted the role of metabolic reprogramming in controlling immunological effector functions, emphasizing the close connection between cell function and metabolism ([@bib62]). In agreement with these results, we observed a substantial increase in both the number of acidic compartments and proteolytic activity of macrophages upon BDQ treatment.

BDQ is a cationic amphiphilic drug, consisting of a hydrophobic ring structure and a hydrophilic side chain with a charged cationic amine group ([@bib13]). Cationic amphiphilic drugs can accumulate in lysosomes through ion trapping ([@bib11]). At neutral pH, they passively diffuse across cell and organelle membranes but when they enter the luminal space of acidic compartments such as lysosomes, the amine group ionizes and becomes membrane-impermeable ([@bib33]). Such lysosomotropic compounds usually increase the lysosomal pH and thus decrease lysosomal enzyme activity ([@bib24]). However, our results reveal instead that BDQ triggers lysosomal activation, upregulating the expression of genes coding for hydrolases and for subunits of the lysosomal proton pump v-ATPase. Consistent with these observations, we observed that BDQ-treated cells significantly increase their ability to degrade DQ-BSA.

Pre-clinical studies have shown that BDQ may induce phospholipidosis, potentially explaining some of the drug's observed toxicities ([@bib13]). Phospholipidosis, which is characterized by the accumulation of phospholipids in lysosomes, resulting in impaired lysosome function, is common upon treatment with cationic amphiphilic compounds ([@bib48]). Various phospholipid species have been described including phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, and lysobisphosphatidic acid ([@bib42]; [@bib65]; [@bib66]; [@bib68]). In BDQ-treated macrophages, we only observed an increase in the amount of phosphatidylinositol and phosphatidylinositol-4-phosphate. The quantity of cardiolipin, phosphatidylethanolamine, and phosphatidylglycerol remained unchanged upon treatment. These observations do not indicate lysosomal dysfunction, but rather a targeted regulation of certain phospholipids by BDQ. In accordance with this idea, 28 genes involved in phospholipid metabolism were differentially expressed in BDQ-treated macrophages. Phosphatidylinositol phosphates regulate many cellular functions, including endosomal trafficking, endoplasmic reticulum (ER) export, autophagy, and phagosome-lysosome fusion ([@bib12]; [@bib29]). These phospholipids may thus be involved in the increase of autophagy and mycobacterial phagosome-lysosome fusion upon BDQ treatment.

Lysosomes are both digestive organelles of the endocytic and autophagic pathways and signaling hubs involved in nutrient sensing, cell growth and differentiation, transcriptional regulation, and metabolic homeostasis ([@bib27]; [@bib28]). In response to nutrients and growth factors, the mechanistic target of the rapamycin complex 1 (mTORC1) is recruited and activated at the lysosomal surface, where it promotes ribosomal biogenesis, translation, and biosynthesis of lipids ([@bib27]; [@bib28]). mTORC1 binds to and phosphorylates TFEB, resulting in its cytosolic sequestration ([@bib44]; [@bib47]). Upon starvation or lysosomal stress, mTORC1 is released from the lysosomal membrane and becomes inactive ([@bib27]; [@bib28]). The release of lysosomal Ca^2+^ activates the phosphatase calcineurin, which de-phosphorylates TFEB and promotes its nuclear translocation ([@bib35]). TFEB then binds to CLEAR (coordinated lysosomal expression and regulation) elements within the promoters of genes involved in autophagy and lysosomal biogenesis and activates their expression ([@bib27]; [@bib28]). We found that TFEB translocates from the cytoplasm to the nucleus in BDQ-treated cells, with the concomitant up-regulation of 85 genes containing CLEAR elements 18 hr after incubation with the drug.

Finding the direct host-cell target of BDQ would have been a major breakthrough, but unfortunately, we were unable to identify the target. However, it is possible that BDQ could modulate the host response by interfering with ion homeostasis inside the lysosome. Greenwood et al. recently showed that BDQ accumulated primarily in host cell lipid droplets ([@bib18]). It is tempting to speculate that these droplets are actually lysosomes. Due to its high hydrophobicity, BDQ might accumulate in lysosomal membranes and thereby change the transmembrane ion permeability. In agreement with this hypothesis, it has been shown that BDQ can accumulate at the lipid membrane of liposomes and act as a H^+^/K^+^ ionophore ([@bib21]). The ensuing lysosomal stress could then facilitate the dissociation of mTOR from the lysosomal membrane ([@bib40]) and the activation of TFEB. Interestingly, BDQ increases the expression of mucolipin 1 gene (*mcoln1*, [Figure 3A](#fig3){ref-type="fig"}, [Figure 3---figure supplement 2A](#fig3s2){ref-type="fig"}), which in turn can activate TFEB. Medina et al. showed indeed that lysosomal Ca^2+^ is released through MCOLN1 and activates calcineurin, which binds and dephosphorylates TFEB ([@bib35]).

A striking feature of BDQ-treated macrophages is their capacity to control pathogenic bacterial infection. BDQ enhances macrophage innate defense mechanisms, including induction of antimicrobial effectors such as nitric oxide, phagosome-lysosome fusion, and autophagy. Other anti-TB drugs have been described to regulate autophagy. INH and PZA promote autophagy activation and phagosomal maturation in MTB-infected murine macrophages ([@bib25]). This process was dependent of bacterial factors and was suggested to be essential for antimycobacterial drug action and for dampening proinflammatory cytokines ([@bib25]). In our system, we did not detect increased autophagy in cells treated with INH, which may also be due to differences in the autophagy response in murine and human macrophages. Altogether, we demonstrate that BDQ is able to boost the innate defenses of human cells.

A growing number of pathogenic bacteria are becoming resistant to antibiotics, making their use less effective. In addition to the development of 'classical' drugs targeting key factors in bacterial physiology, host-directed therapy (HDT) has emerged as approach that could be used in adjunct with existing or future antibiotics ([@bib32]). For example, metformin, an FDA-approved drug for type II diabetes, increases the production of mitochondrial reactive oxygen species and stimulates phagosome-lysosome fusion by activating the 5′-adenosine monophosphate-activated protein kinase (AMPK) ([@bib51]), and recent studies suggest that metformin provides better outcomes in TB patients, especially those with diabetes mellitus ([@bib67]). Pathogens manipulate host-signaling pathways to subvert innate and adaptive immunity. It might thus be possible to reprogram the host immune system to better control or even kill bacteria. For instance, MTB has developed several strategies to counteract autophagy, including the product of the enhanced intracellular survival (Eis) gene, which limits ROS generation ([@bib49]). Our results clearly show that BDQ can bypass these escape mechanisms and allow more effective control of bacterial infection. We also showed that BDQ potentiates the activity of other anti-TB drugs, independently of its bactericidal activity on MTB. Hence, our work opens new avenues for downstream evaluation of the potential use of BDQ as a potent drug in HDT.

Materials and methods {#s4}
=====================

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\                                              Designation                                     Source or\                                                                                                       Identifiers                                                      Additional\
  (species)\                                                                                                 reference                                                                                                                                                                         information
  or resource                                                                                                                                                                                                                                                                                  
  ---------------------------------------------------------- ----------------------------------------------- ---------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------- -----------------------------------------------------------------------
  Buffy coats (*Homo sapiens*)                               PBMC                                            Etablissement Français du sang (EFS)                                                                                                                                              

  Cell line (*Homo sapiens*)                                 HEK 293 cell line                               Obtained from Dr. Craig T. January, University of Wisconsin--Madison                                                                                                              

  Cell line (*Homo sapiens*)                                 HEK 293 cell line stably expressing hERG        Obtained from Dr. Craig T. January, University of Wisconsin--Madison                                                                                                              

  Strain, strain background (*Mycobacterium tuberculosis*)   H37Rv                                           PMID:[12574362](https://www.ncbi.nlm.nih.gov/pubmed/12574362)                                                                                                                     

  Strain, strain background (*Salmonella* Typhimurium)       *S.* Typhimurium                                PMID:[25793259](https://www.ncbi.nlm.nih.gov/pubmed/25793259)                                                                                                                     

  Strain, strain background (*Staphylococcus aureus*)        *S. aureus*                                     PMID:[25793259](https://www.ncbi.nlm.nih.gov/pubmed/25793259)                                                                                                                     

  Antibody                                                   Donkey anti-\                                   Thermo Fisher                                                                                                    Cat. \#: A-31572\                                                IF (1:500)
                                                             Rabbit Secondary Antibody, Alexa Fluor 555                                                                                                                       RRID:[AB_162543](https://scicrunch.org/resolver/AB_162543)       

  Antibody                                                   Goat anti-Mouse\                                Thermo Fisher                                                                                                    Cat. \#: A-21424\                                                IF (1:500)
                                                             Secondary Antibody, Alexa Fluor 555                                                                                                                              RRID:[AB_141780](https://scicrunch.org/resolver/AB_141780)       

  Antibody                                                   Mouse monoclonal anti-LC3                       MBL                                                                                                              Cat. \#: M152-3\                                                 IF (1:100)
                                                                                                                                                                                                                              RRID:[AB_1953013](https://scicrunch.org/resolver/AB_1953013)     

  Antibody                                                   Rabbit IgG HRP Linked Whole Ab                  GE Healthcare                                                                                                    Cat. \#: NA934\                                                  WB (1:1000)
                                                                                                                                                                                                                              RRID:[AB_2722659](https://scicrunch.org/resolver/AB_2722659)     

  Antibody                                                   Rabbit polyclonal anti- α/β-Tubulin             Cell Signaling Technology                                                                                        Cat. \#: 2148S\                                                  WB (1:1000)
                                                                                                                                                                                                                              RRID:[AB_2288042](https://scicrunch.org/resolver/AB_2288042)     

  Antibody                                                   Rabbit polyclonal anti-LC3B                     Abcam                                                                                                            Cat. \#: Ab48394\                                                WB (1:1000)
                                                                                                                                                                                                                              RRID:[AB_881433](https://scicrunch.org/resolver/AB_881433)       

  Antibody                                                   Rabbit polyclonal anti-SQSTM1/p62               Cell Signaling Technology                                                                                        Cat. \#: 5114S\                                                  WB (1:1000)
                                                                                                                                                                                                                              RRID:[AB_10624872](https://scicrunch.org/resolver/AB_10624872)   

  Antibody                                                   Rabbit polyclonal anti-TFEB                     Thermo Fisher                                                                                                    Cat. \#: PA5-65566\                                              IF (1:100)
                                                                                                                                                                                                                              RRID:[AB_2662642](https://scicrunch.org/resolver/AB_2662642)     

  Commercial assay or kit                                    Griess Reaction Assay                           Promega                                                                                                          Cat. \#: G2930\                                                  
                                                                                                                                                                                                                              RRID:[SCR_006724](https://scicrunch.org/resolver/SCR_006724)     

  Commercial assay or kit                                    Illumina TruSeq RNA Sample Preparation kit v2   Illumina                                                                                                         Cat. \#: RS-122-2001/2002\                                       
                                                                                                                                                                                                                              RRID:[SCR_010233](https://scicrunch.org/resolver/SCR_010233)     

  Commercial assay or kit                                    MTT Cell Proliferation Assay kit                Trevigen                                                                                                         Cat. \#: 4890--25K\                                              
                                                                                                                                                                                                                              RRID:[SCR_012449](https://scicrunch.org/resolver/SCR_012449)     

  Commercial assay or kit                                    PierceTM BCA Protein Assay kit                  Thermo Fisher                                                                                                    Cat. \#: 23227                                                   

  Commercial assay or kit                                    RNeasy Mini kit                                 Qiagen                                                                                                           Cat. \#: 74104\                                                  
                                                                                                                                                                                                                              RRID:[SCR_008539](https://scicrunch.org/resolver/SCR_008539)     

  Commercial assay or kit                                    Seahorse XF Cell Mito Stress Test Kit           Agilent Technologies                                                                                             Cat. \#: 103708--100                                             

  Commercial assay or kit                                    Seahorse XF Glycolytic rate Assay kit           Agilent Technologies                                                                                             Cat. \#: 103710--100                                             

  Chemical compound, drug                                    Bedaquiline                                     Combi-Blocks                                                                                                     Cat. \#: QV-7478                                                 

  Chemical compound, drug                                    BAPTA-AM                                        Sigma-Aldrich                                                                                                    Cat. \#: A1076                                                   

  Commercial assay or kit                                    Image-IT TMRM                                   Thermo Fisher                                                                                                    Cat. \#: I34361                                                  

  Commercial assay or kit                                    LysoTracker DND-99                              Thermo Fisher                                                                                                    Cat. \#: L7528                                                   

  Commercial assay or kit                                    MitoSOX Red                                     Thermo Fisher                                                                                                    Cat. \#: M36008                                                  

  Commercial assay or kit                                    MitoTrackerTM Deep Red FM                       Thermo Fisher                                                                                                    Cat. \#: M22426                                                  

  Commercial assay or kit                                    Fluo-8 AM                                       Abcam                                                                                                            Cat. \#: Ab142773                                                

  Commercial assay or kit                                    DQ Green BSA                                    Thermo Fisher                                                                                                    Cat. \#: D12050                                                  

  Commercial assay or kit                                    SuperScript III Reverse Transcriptase           Thermo Fisher                                                                                                    Cat. \#: 18080093                                                

  Commercial assay or kit                                    Power SYBR Green PCR Master Mix                 Thermo Fisher                                                                                                    Cat. \#: 4367659                                                 

  Sequenced-based reagent                                    RT-qPCR primers                                 This paper                                                                                                                                                                        See [Supplementary file 1](#supp1){ref-type="supplementary-material"}

  Sequenced-\                                                siRNA: nontargeting control                     Dharmacon                                                                                                        Cat. \#: D-001810--10-\                                          
  based reagent                                                                                                                                                                                                               05                                                               

  Sequenced-based reagent                                    siRNA: ON-TARGETplus Human\                     Dharmacon                                                                                                        Cat. \#: L-009798--00-\                                          
                                                             TFEB (7942) siRNA -\                                                                                                                                             0005                                                             
                                                             SMARTpool                                                                                                                                                                                                                         

  Software, algorithm                                        GraphPad Prism                                  GraphPad Prism (<https://graphpad.com>)                                                                          RRID:[SCR_002798](https://scicrunch.org/resolver/SCR_002798)     Version 7

  Software, algorithm                                        ClueGO (Cytospace plug-in)                      <http://apps.cytoscape.org/apps/cluego>                                                                          RRID:[SCR_005748](https://scicrunch.org/resolver/SCR_005748)     

  Software, algorithm                                        DESeq2                                          [https://bioconductor.org/packages/release/](https://bioconductor.org/packages/release/bioc/html/DESeq2.html)\   RRID:[SCR_015687](https://scicrunch.org/resolver/SCR_015687)     Version 1.18.1
                                                                                                             [bioc/html/DESeq2.html](https://bioconductor.org/packages/release/bioc/html/DESeq2.html)                                                                                          

  Software, algorithm                                        Icy                                             <http://icy.bioimageanalysis.org/download/>                                                                      RRID:[SCR_010587](https://scicrunch.org/resolver/SCR_010587)     Version 1.0

  Software, algorithm                                        Seahorse Wave                                   [http://www.agilent.com/en-us/products/](http://www.agilent.com/en-us/products/cell-analysis-)\                  RRID:[SCR_014526](https://scicrunch.org/resolver/SCR_014526)     
                                                                                                             [cell-analysis-](http://www.agilent.com/en-us/products/cell-analysis-)(seahorse)/software-download-for-\                                                                          
                                                                                                             wave-desktop                                                                                                                                                                      

  Software, algorithm                                        ImageJ                                          <http://imagej.nih.gov/ij>                                                                                       RRID:[SCR_003070](https://scicrunch.org/resolver/SCR_003070)     
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Ethics statement {#s4-1}
----------------

Buffy coats were obtained from healthy donors after informed consent. The blood collection protocols were approved by both the French Ministry of Research and a French Ethics Committee. The blood collection was carried out in accordance with these approved protocols by the Etablissement Français du Sang (EFS, n°12/EFS/134).

Macrophage, MTB and infection {#s4-2}
-----------------------------

Blood mononuclear cells were isolated from buffy coats by Lymphocytes Separation Medium centrifugation (Eurobio, Les Ulis, France). CD14^+^ monocytes were isolated by positive selection using CD14 microbeads (Miltenyi Biotec, Bergisch Gladbach, Germany) and were allowed to differentiate into macrophages in the presence of granulocyte macrophage colony-stimulating factor (GM-CSF, 20 ng/mL; Miltenyi Biotec) over a 6-day period. To exclude potential differences due to the MTB bacillary load between treated and untreated cells, macrophages were infected with BDQ-resistant MTB strain H37Rv (BDQr-MTB) expressing green-fluorescent protein (GFP). Briefly, exponentially growing MTB carrying the pEGFP plasmid ([@bib53]) was plated during 4 weeks on Middlebrook 7H11 agar supplemented with OADC (Becton Dickinson, Franklin Lakes, New Jersey) and containing 0.3 µg/mL BDQ. Some clones were then selected. Resistance to BDQ was confirmed (i) by bacterial culture in Middlebrook 7H9 Broth (Becton Dickinson) supplemented with albumin-dextrose-catalase (ADC, Becton Dickinson) and 0.3 µg/mL BDQ, and (ii) by confirming the mutation in the ATP synthase gene. The *atpE* gene was PCR-amplified using primers (forward: 5-TCGTGTTCATCCTGATCTCCA-3; reverse: 5-GACAATCGCGCTCACTTCAC-3) and the PCR products were sent to Eurofins for sequencing. All the selected mutants carried a mutation in the *atpE* gene as described previously ([@bib2]). Only mutant with similar growth rate (in liquid medium and in macrophages) as the wild-type strain has been used for further experiments. Before infection, bacteria were washed and resuspended in 1 mL PBS. Clumps were disassociated by 50 passages through a needle, and then allowed to sediment for 5 min. The density of bacteria in the supernatant was verified by measuring the OD600 and aliquot volumes defined to allow 0.5 bacterium-per-cell infections. After 2 hr of incubation at 37°C, infected cells were thoroughly washed in RPMI 1640 to remove extracellular bacteria and were incubated in fresh medium.

Cell viability assay {#s4-3}
--------------------

Cell viability was determined using the LDH Cytotoxicity Assay kit or the MTT assay kit (Abcam), according to manufacturer's instructions.

Resazurin assay determination of the minimal inhibitory concentration (MIC) {#s4-4}
---------------------------------------------------------------------------

The microdilution test was performed in 96-well plates as previously described ([@bib38]). Briefly, BDQr-MTB and H37Rv were cultured in 7H9 liquid medium containing 2-fold dilutions of BDQ (from 80 to 0.039 µg/mL) during 6 days. The dye resazurin (Sigma) was then added to each well at a final concentration of 0.003%. After 24 hr, the absorbance was measured at 570 nm.

High-content screening {#s4-5}
----------------------

Mφs (10^5^ cells/mL) were plated in 96-well tissue culture plates (CellCarrier-96 Ultra Microplates) and were infected with drug-susceptible H37Rv or BDQr-MTB expressing the GFP protein. Cells were then treated with BDQ (5 µg/mL) for 18 hr or 5 days. Cells were fixed with 4% paraformaldehyde for 1 hr at room temperature and were strained with HCS CellMask Blue stain (HCS, Invitrogen Molecular Probes, 2 µg/mL) and Hoechst 33342 (5 µg/mL) at 4°C in PBS. Confocal images were acquired using the automated fluorescence microscope Opera Phenix High Content Screening System (Perkin Elmer Technology, Waltham, Massachusetts), with a 20x air objective. Images were analyzed using Columbus Conductor Database (Perkin Elmer Technologies).

RNA isolation, library preparation and sequencing {#s4-6}
-------------------------------------------------

Total RNA from macrophages was extracted using QIAzol lysis reagent (Qiagen, Hilden, Germany) and purified over RNeasy columns (Qiagen). The quality of all samples was assessed with an Agilent 2100 bioanalyzer (Agilent Technologies, Santa Clara, CA) to verify RNA integrity. Only samples with good RNA yield and no RNA degradation (ratio of 28S to 18S,\>1.7; RNA integrity number,\>9) were used for further experiments. cDNA libraries were prepared with the Illumina TruSeq RNA Sample Preparation Kit v2 and were sequenced on an llumina HiSeq 2500 at the CHU Sainte-Justine Integrated Centre for Pediatric Clinical Genomics (Montreal, Canada).

STAR v2.5.0b ([@bib14]) was used to map RNA-seq reads to the hg38 reference genome and quantify gene expression (option-quantMode GeneCounts) by counting the fragments overlapping the Ensembl genes (GRCh38 v. 83). Differential expression analysis was performed using a generalized linear model with the R Bioconductor package DESeq2 v1.18.1 ([@bib31]) on the 12,584 genes with at least one count-per-million (CPM) read in at least four samples. The model formula used in DESeq2 (\~Donor + Infection + Infection:Donor + Infection:Treatment + Donor:Treatment) contained: the main effects for Donor and Infection, interactions of Donor with Infection and Treatment to adjust for various responses to infection and treatment between donors, and a nested interaction of Infection with Treatment because we were interested in the infection-status-specific treatment effects. The latter was used to extract differentially expressed genes between treated and untreated samples under the infected and uninfected conditions. p-Values were adjusted for multiple comparisons using the Benjamini-Hochberg method producing an adjusted P-value or false-discovery rate (FDR).

Gene ontology (GO) enrichment analyses were performed using the Cytoscape app ClueGO (version 2.5.3) ([@bib6]). The following parameters were used: only pathways with pV ≤0.01, Minimum GO level = 3, Maximum GO level = 8, Min GO family \>1, minimum number of genes associated to GO term = 5, and minimum percentage of genes associated to GO term = 8. Enrichment p-values were calculated using a hypergeometric test (p-value\<0.05, Bonferroni corrected).

Measurement of glycolysis {#s4-7}
-------------------------

Measurement of glycolysis was done using the Glycolytic rate assay kit (Seahorse, Agilent Technologies), following the manufacturer's protocol. Briefly, cells were seeded in Xe96 plates treated with BDQ for 24 hr. The cells were then incubated in the assay medium (Seahorse XF Base Medium without phenol, 2 mM glutamine, 10 mM glucose, 1 mM pyruvate and 5.0 mM HEPES) at 37°C, during 1 hr. Extracellular acidification rate (ECAR, milli pH/min) and oxygen consumption rate (OCR, pmol/min) were measured using the Seahorse Bioscience XFe96 Analyzer.

Lipidomic {#s4-8}
---------

Cells were treated with BDQ during 18 hr and them lysed in water during 10 min at 37°C. Samples were heated at 90°C during 40 min in order to inactivate MTB, and were then washed three times to remove salts and contaminants that could preclude the analysis. Prior to mass spectrometry analysis, the 2,5-dihydroxybenzoic acid (Sigma-Aldrich, Saint-Louis, Missouri) matrix was added at a final concentration of 10 mg/mL in a chloroform/methanol mixture at a 90:10 (v/v) ratio; 0.4 μL of a cell solution at a concentration of 2 × 10^5^ to 2 × 10^6^ cells/mL, corresponding to ∼100--1,000 cells per well of the MALDI target plate (384 Opti-TOF 123 mm ×84 mm, AB Sciex), and 0.6 μL of the matrix solution were deposited on the MALDI target plate, mixed with a micropipette, and left to dry gently. MALDI-TOF MS analysis was performed on a 4800 Proteomics Analyzer (with TOF-TOF Optics, Applied Biosystems, Foster City, California) using the reflectron mode. Samples were analyzed operating at 20 kV in the negative and positive ion mode. Mass spectrometry data were analyzed using Data Explorer version 4.9 from Applied Biosystems.

Staining and quantification of acidic compartments {#s4-9}
--------------------------------------------------

Cells were incubated with LysoTracker DND-99 (100 nM; Thermo Fisher, Waltham, Massachusetts) during 1 hr at 37°C. Cells were then fixed with 4% paraformaldehyde at room temperature (RT) for 1 hr. Fluorescence was analyzed using a CytoFLEX Flow Cytometer (Beckman Coulter, Brea, California). More than 10,000 events per sample were recorded. The analysis was performed using the FlowJo software.

LysoTracker staining was also analyzed using a Leica TCS SP5 Confocal System. Briefly, cells were washed twice with PBS after incubation with LysoTracker DND-99 (1 µM), fixed with 4% paraformaldehyde for 1 hr at RT, stained with DAPI (1 µg/mL, Thermo Fisher) during 10 min mounted on a glass slide using Fluoromount mounting medium (Thermo Fisher). Quantification of LysoTracker staining was performed using Icy software.

Quantification of lysosomal proteolytic activity {#s4-10}
------------------------------------------------

Macrophages were activated with heat-killed MTB and treated with BDQ during 18 hr or 48 hr. Cells were then incubated with DQ-Green BSA (10 µg/mL; Thermo Fisher) for 1 hr at 37°C. The hydrolysis of the DQ-Green BSA by lysosomal proteases produces brightly fluorescent peptides. Cells were washed and incubated further in culture medium for 3 hr to ensure that DQ BSA had reached the lysosomal compartment. Cells were detached and were fixed with 4% paraformaldehyde and the fluorescence was analyzed using a CytoFLEX Flow Cytometer (Beckman Coulter).

Determination of bacterial counts {#s4-11}
---------------------------------

Macrophages were lysed in distilled water with 0.1% Triton X-100. MTB was enumerated as previously described [@bib53] and plated on 7H11. CFUs were scored after three weeks at 37°C. *S. aureus* and *S.* Typhimurium were plated on Luria-Bertani agar and CFUs were counted after 1 day at 37°C.

Indirect immunofluorescence {#s4-12}
---------------------------

Macrophages (4 × 10^5^ cells/mL) were grown on 12 mm circular coverslips in 24-well tissue culture plates for 24 hr in cell culture medium, followed by BDQ treatment. Cells were fixed with 4% paraformaldehyde for 1 hr at RT, and were then incubated for 30 min in 1% BSA (Sigma-Aldrich) and 0.075% saponin (Sigma-Aldrich) in PBS, to block nonspecific binding and to permeabilize the cells. Cells were incubated with anti-LC3 (MBL, Woburn, MA) during 2 hr at RT. Alternatively, cells were fixed with cold methanol for 5 min, and were then incubated for 10 min in PBS containing 0.5% saponin. Cells were stained with anti-TFEB (Thermo Fisher) overnight at 4°C. Cells were washed and incubated with Alexa Fluor 555 secondary antibody (Thermo Fisher) for 2 hr. Nuclei were stained with DAPI (1 µg/mL) during 10 min. After labeling, coverslips were set in Fluoromount G medium containing 1 µg/ml 4′,6-diamidino-2-phenylindole (DAPI) (SouthernBiotech, Birmingham, Alabama) on microscope slides. Fluorescence was analyzed using Leica TCS SP5. Quantification of TFEB staining was performed using Icy software. LC3B puncta were analysed by confocal microscopy and quantified using ImageJ. Infected cells were manually segmented, thresholded and puncta counted using Analyze Particles. Dot plots represent the mean values of at least 83 cells from two donors. Error bars depict the SD.

Quantitative reverse transcription PCR (RT-qPCR) {#s4-13}
------------------------------------------------

Reverse transcription of mRNA to cDNA was done using SuperScript III Reverse Transcriptase (Thermo Fisher) followed by amplification of cDNA using Power SYBR Green PCR Master Mix (Thermo Fisher). All primers used in this study are listed in [Supplementary file 1](#supp1){ref-type="supplementary-material"}. Reactions were performed using a StepOnePlus Real-Time PCR System Thermal Cycling block (Applied Biosystems). The relative gene expression levels were assessed according to the 2^-ΔCt^ method ([@bib39]).

Western blot analysis {#s4-14}
---------------------

Cells were lysed with RIPA buffer (Thermo Fisher) containing protease inhibitor cocktails (Roche) and stored at −80°C. Protein concentration was determined using the BCA protein assay kit (Thermo Fisher) according to the manufacturer instructions. 20 µg of total protein were loaded on a NUPAGE 4--12% Bis-Tris polyacrylamide gel (Thermo Fisher) and transferred to PVDF membranes (iBlot, Thermo Fisher). The membranes were blocked with TBS-0.1% Tween20, 5% non-fat dry milk for 30 min at RT and incubated overnight with primary antibodies against α-β-Tubulin, p-62 (Cell Signaling, Danvers, Massachusetts) and LC3 (Abcam, Cambridge, United Kingdom). Membranes were washed in TBS-Tween and incubated with secondary HRP-conjugated antibody (GE Healthcare, Chicago, IL) at RT for 1 hr. Membranes were washed and exposed to SuperSignal West Femto Maximum Sensitivity Substrate (Thermo Fisher). Detection and quantification of band intensities was performed using Azure Imager C400 (Azure Biosystems, Dublin, CA) and ImageJ software (version 1.51).

Infection *S. aureus* and *S.* Typhimurium {#s4-15}
------------------------------------------

*S. aureus* and *S.* T*yphimurium* were grown in Luria-Bertani broth. Bacteria were washed three times and resuspended in PBS. The density of bacteria was estimated by measuring the OD~600~. Cells were then infected at a multiplicity of infection of 2:1. After 1 hr of infection, cells were extensively washed and incubated for 1 hr in culture medium supplemented with gentamicin (100 µg/mL). After washing, cells were cultured with different concentrations of BDQ and gentamicin (5 µg/mL).

Measurement of nitric oxide {#s4-16}
---------------------------

NO was measured by Griess reaction assay (Promega, Madison, Wisconsin) according to the manufacturer\'s instructions. Briefly cell culture supernatants were incubated with sulfanilamide solution during 10 min followed by additional 10 min with N-1-napthylethylenediamine dihydrochloride. The absorbance was measured at 520 nm.

Mitochondrial membrane potential {#s4-17}
--------------------------------

Cells were stained with Image-IT TMRM (10 nM, Thermo Fischer) during 30 min at 37°C or with MitoTracker Deep Red (100 nM, Thermo Fisher) during 45 min at 37°C. Cells were washed in PBS and detached from culture plates with 0.05% Trypsin-EDTA. Fluorescence was analyzed using a CytoFLEX Flow Cytometer (Beckman Coulter).

Measurement of oxygen consumption {#s4-18}
---------------------------------

The oxygen consumption rate was measured using the XF Cell Mito Stress Test Kit (Seahorse, Agilent Technologies) according to the manufacturer's protocol. Briefly, cells were seeded in Xe96 plates and treated with BDQ for 24 hr. The test was performed by adding oligomycin (1 µM), FCCP (1 µM), rotenone and antimycin (0.5 µM) at the indicated time points.

Mitochondrial ROS assay {#s4-19}
-----------------------

Cells were incubated with MitoSOX Red (5 µM, Thermo Fisher) during 10 min at 37°C. Cells were washed in PBS and detached from culture plates with 0.05% Trypsin-EDTA. Fluorescence was analyzed using a CytoFLEX Flow Cytometer (Beckman Coulter).

Calcium measurement assay {#s4-20}
-------------------------

Cells were treated with BDQ for 1 to 18 hr, then labeled with Fluo-8 AM (4 µM, Abcam) during 1 hr. Cells were washed twice with PBS and fluorescence was analyzed using FLUOstar Omega (BMG Labtech, Ortenberg, Germany).

siRNA silencing of TFEB {#s4-21}
-----------------------

siRNA transfection was performed as previously described ([@bib57]). Briefly, macrophages were transfected using the lipid-based HiPerfect system (Qiagen) and an ON-TARGETplus SMARTpool siRNA targeting TFEB (50 nM) and a non-targeting siRNA (scramble) (Dharmacon). After 6 hr, cells were washed and incubated in complete culture medium for an additional 2 days. The inactivation of TFEB was confirmed RT-qPCR at 48 hr post-transfection.

Chromatin immunoprecipitation assay {#s4-22}
-----------------------------------

The protocol was adopted from [@bib8]. Briefly, cells treated were fixed in 1% formaldehyde during 10 min. Glycine was then added to a final concentration of 0.15 M. Cells were washed with PBS and were lysed with ice-cold RIPA buffer supplemented with protease inhibitors (Roche). The chromatin fraction was sonicated to obtain fragments from 100 to 500 bp and were coupled with DynaBeads protein G coupled to the anti-TFEB antibody (D2O7D, Cell Signaling) overnight at 4°C. Immune complexes were eluted from the beads with 1% SDS in TE. After treatment with RNaseA and proteinase K, protein-DNA cross-links were reversed by adding NaCl 5M and incubated at 65°C overnight. Chromatin immunoprecipitation analysis was performed by qPCR using Power SYBR Green PCR Master Mix (Thermo Fisher). The primers for *gla* and *mcoln1* were used from [@bib37].

Quantification and statistical analysis {#s4-23}
---------------------------------------

Data are expressed as means ± standard deviations (SD). Statistical analyses were performed with Prism software (GraphPad Software Inc), using the t test and one-way analysis of variance (ANOVA) as indicated in the figure legends. A p value of \< 0.05 was considered to be significant.

Data availability {#s4-24}
-----------------

The raw fastq files of BDQ-treated cells have been deposited in NCBI\'s Gene Expression Omnibus ([@bib15]) and are accessible through GEO Series accession number GSE133145. The raw fastq files of cells stimulated with heat-killed MTB or treated with different antibiotics are accessible through GEO Series accession numbers GSE143627 and GSE143731.
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**Acceptance summary:**

This paper provides evidence that the antibiotic bedaquiline not only has direct anti-microbial effects but may also act on host cells to enhance their capacity for killing bacteria. Bedaquiline is an important antibiotic for the treatment of tuberculosis, and a better understanding of its activities is important for developing next-generation therapeutics for this globally significant disease. More-broadly, understanding the host-directed effects of antibiotics is also significant for other bacterial infections for which drug resistance is increasing.

**Decision letter after peer review:**

\[Editors' note: the authors submitted for reconsideration following the decision after peer review. What follows is the decision letter after the first round of review.\]

Thank you for submitting your work entitled \"The antibiotic bedaquiline activates host macrophage innate immune resistance to bacterial infection\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by a Reviewing Editor and a Senior Editor.

Our decision has been reached after consultation between the reviewers. We found that the work addresses an important topic and is interesting. However, the reviewers have raised substantial technical concerns. Therefore, the decision is to reject your manuscript without requesting a revision. Nevertheless, in addition to the individual reviews, we are providing a consolidated review (below) that captures the consensus of the three reviewers in case you feel that the concerns are easily addressable within a reasonable timeframe.

1\) A major concern is that the manuscript does not cleanly demonstrate that the effects of BDQ observed on MTB growing in cells is in fact due to the effects of BDQ on the host cells vs. effects of BDQ on MTB. The use of a BDQ resistant mutant is a nice attempt to address this concern, but it is not entirely satisfactory. First, the data shown in Figure 1---figure supplement 2C demonstrate that BDQ (5µg/mL) does appear to have an effect on growth of the resistant mutant. Second, even if growth of the bacteria is unimpeded in broth, the antibiotic may still have an effect on the bacteria in cells. Even a minor effect on MTB (e.g., lysis of a few bacteria) might have a large effect on the host response. Unless this central concern can be satisfactorily addressed (which we fear it may not be) then we do not feel the paper would be a strong candidate for *eLife*.

2\) Another major concern relates to the presentation of the RNAseq data in Figure 1A-B and Figure supplement 3A-B. Figure 1AB shows the effect of BDQ on MTB-infected macrophages, whereas Figure supplement 3A-B shows the effect of BDQ on uninfected macrophages. If BDQ acts on host cells independent of an effect on bacteria, then we would expect similar genes to be induced in both conditions. However, the data are presented only at the level of GO-term annotations. We require gene-level expression data comparing gene induction in all four conditions (+/- BDQ and +/- MTB) in a single analysis so that we can assess whether in fact the effects of BDQ are similar +/- MTB. It may well be that MTB modulates the host response to BDQ, e.g., via activation of TLRs. In such a case, it might be useful to compare the response of cells infected with live TB +/- BDQ with the response to cells treated with TLR agonists or killed bacteria +/- BDQ. If, however, the main effects of BDQ on host gene expression only appear to occur in conjunction with infection with live MTB, then we would be concerned that the effects of BDQ are via their effects on MTB and not direct host-directed effects.

3\) Another major concern is that there is no direct evidence that the apparent effects of BDQ on MTB growing in cells is due to induction of TFEB. This should be shown with TFEB mutant cells. These cells could also be used to show that the induction of lysosomal-related genes and increased lysotracker staining by BDQ is due to TFEB activation.

4\) As raised by reviewer 2, it is imperative to show that the synergy between BDQ and PZA on the BDQ-resistant mutant does not occur in broth.

Other comments:

\- A MIC for BDQ on the resistant mutant should be reported.

\- Figure 1---figure supplement 2B is missing information about what concentration of BDQ was used.

\- Reviewer 2 raised a number of questions about the data in Figure 1---figure supplement 2C that should be addressed.

\- As raised by reviewer 3, the proposed mechanism connecting BDQ to calcium and TFEB activation is only weakly supported by data. The authors should consider toning down their conclusions related to this part of the paper.

Reviewer \#1:

Tuberculosis remains a major global problem and kills more people than any other single pathogen. This paper addresses the mechanism of action of one of the most important new tuberculosis drugs, bedaquiline (BDQ), and shows that in addition to its well-known direct anti-microbial effects, BDQ also has significant \'host-directed\' effects that can contribute to its anti-microbial activity. In particular, BDQ is shown to enhance lysosomal activity in macrophages. This appears to be via activation of the host transcription factor, TFEB.

In general the paper is well-written, and the experiments are well-described and well-performed. There is significant current interest in the idea of host-directed therapies for TB, and the idea that a major new TB drug might act in part via its effects on host cells is interesting and potentially very important. I have only a few minor comments:

1\) Transcriptional profiling is performed on both MTB-infected and in uninfected cells. It is claimed that the effects of BDQ are \"similar\" in both situations. However, the way the data are presented makes it hard to see how similar or different the effects of BDQ are +/- MTB. Could the authors present a heat-map (indicating key genes, particularly the lysosomal signature) with all four conditions (+/- MTB, +/- BDQ) in a single analysis/panel? If there are significant differences, it might be relevant to comment on these.

2\) A weakness of the manuscript is that the direct host-cell target of BDQ is not identified. Thus, the mechanism leading to TFEB induction is unclear. However, I tend to feel that identification of the target of BDQ is beyond what could be reasonably asked of this study. However, perhaps the authors could at least briefly discuss what the host cell target of BDQ might be and acknowledge that they have not identified it. In addition, the evidence that the effects of BDQ require TFEB is only indirect. It would thus be desirable, if feasible, for the authors to show, e.g., with TFEB knock out cells, that the effects of BDQ on lysosome-related gene induction does require TFEB.

Reviewer \#2:

The manuscript by Giraud-Gatineau et al. concludes that the newest anti-tuberculosis antibiotic, bedaquiline (BDQ), works by not only inhibiting ATP synthase in the bacterium, but also by synergistically working directly on host macrophages to boost their antimicrobial effects during infection. There have been many reports of similar kinds of effects of different antibiotic regimens on activating immune responses the host, but nearly all suffer from the inherent difficulty in conclusively determining whether the \"host effects\" of the antibiotic are due to direct action on macrophage pathways or whether the effects on the host are secondary to the effects of the antibiotic on the physiology of the bacteria. Indeed, each of the papers cited by the authors on this subject suffer from this problem, and the field remains murky.

It would be an exciting finding that BDQ activates host macrophage pathways (perhaps by partial inhibition of the host ATP synthase?), but unfortunately my main criticism of this paper is that I find that there are multiple issues that center around the main problem of whether BDQ actually increases the antibacterial capacity of macrophages by directly activating host pathways. I certainly appreciate the difficulty of the task, and the authors consider bacterial load as one potential factor by using a BDQ-resistant mutant, but many of my concerns relate to the data itself of these key experiments, as well as the possibility of effects on bacterial physiology induced by the antibiotic. For example, even a small amount of lysis of the bacteria could influence host transcriptional responses. Likewise, it seems that comparing resistance of a bacterium in culture vs. in a cell doesn\'t necessarily show that the effect is on the host. It seems likely that the antibiotic is still working solely on the bug, but the host environment sensitizes the bacterium to the antibiotic.

1\) It seems likely to me that the transcriptional (Figure 1) and functional effects (Figure 2) of BDQ on infected macrophages is due to indirect effects on bacterial physiology. The use of the BDQ-resistant mutant is an important experiment, but I have doubts that the concentration used for the macrophage infection studies (5µg/mL) does not have any effect on the bacteria. This concentration apparently inhibits the growth of the resistant mutant Figure 1---figure supplement 2C inside macrophages, and this could be due to either activation of antimicrobial host effects or partial inhibition of bacterial growth. It is not clear what effects this concentration has on the bacteria, the mutant was selected on 0.3 µg/mL BDQ, and I could not find an MIC stated in the manuscript. The growth curve of bacteria grown in axenic culture +/- BDQ (panel B) is missing any information about the concentration of BDQ used, and there is no direct comparison of the growth kinetics between wild-type and mutant bacteria at 5 µg/mL. Moreover, the assumption is that treatment with 5µg/mL of BDQ doesn\'t change the bacteria at all, and thus any differences must be due to host modulation, yet I think there are multiple reasons to doubt this.

2\) There are a number of other worrisome details about the experiment displayed in Figure 1---figure supplement 2C. First, it is curious that neither the wild-type nor resistant bacteria grew very well between the 18hour and 5day time points in the absence of BDQ. It appears they double at best, but much more would be expected. Second, the BDQ-resistant mutant didn\'t grow at all over this 4+ day time course in the presence of 5µg/mL BDQ. It seems unlikely to me that this effects of BDQ are solely due to host activation. Third, why are the CFU levels of the mutant bacteria so much higher than the wild-type at 18 hours?

3\) It seems important to demonstrate in all of their bacterial infections, including Figure 4, that the macrophage monolayers are intact and of equal density amongst all the treatments. Indeed, while the authors test the effects of BDQ on macrophage viability in the absence of bacteria, it seems important to assess its effect during the heightened inflammatory response during infection.

4\) I believe that the results with the host effects of BDQ would be more conclusive if they could show that treatment with different antibiotics gives rise to different results.

5\) The authors also perform treatment of macrophages with BDQ in the absence of infection, and claim that similar pathways are activated, inferring that these effects are independent of the presence of bacteria. Unfortunately, these comparisons were evaluated at the level of GO pathway annotation, and I believe strongly that if BDQ is directly activating gene expression, perhaps via PTFB, that the comparison should be performed at the gene level, i.e. as done in Figure 2A.

6\) I find the conclusion drawn from the apparent synergy btw PZA and BDQ is misleading for two reasons. First of all, given the residual sensitivity of the resistant mutant to high levels of BDQ, it seems imperative that this synergy be tested in culture. Second, given the model that BDQ activates host antimicrobial activities, I expect that BDQ would also synergize with other antibiotics besides PZA.

7\) Much of the lysosome results in Figure 2 is complicated by the mild sensitivity of the resistant strain to BDQ. The one experiment that is interesting is the no-infection in panel G, but there is only a correlation, there is no evidence provided that this is the host effect of BDQ.

Reviewer \#3:

In this manuscript, Giraud-Gatineau et al. describe how bedaquiline (BDQ), an antibiotic in clinical use for TB, activates bactericidal functions in human primary macrophages. Transcriptional analysis of such treated macrophages leads them to examine the autophagy-lysosomal pathway, which they find is upregulated and necessary for the effect of BDQ in reducing *M. tuberculosis* load in infected macrophages in vitro. Finally, they show that transcription factor TFEB is activated by BDQ, and that the activity of BDQ in macrophages is dependent on calcium, suggesting that the MCOLN1-calcineurin-TFEB pathway described by Medina et al., (2015) is implicated.

Overall, the concept of antibiotics serving dual functions as host-directed therapies is appealing and of great interest. However, there are several major concerns that must be addressed:

1\) The proposed mechanism of enhancement of bactericidal activity is through TFEB, but the only evidence presented is correlative (TFEB immunofluorescence showing TFEB in the nucleus). This must be directly tested using loss-of-function approaches.

2\) Similarly, the implication from the RNAseq, LysoTracker, and TFEB IF is that TFEB upregulates the genes responsible for lysosomal biogenesis and autophagy, thus increasing bacterial clearance. The inducible recruitment of TFEB to relevant promoters must be directly tested.

3\) The mechanism connecting BDQ to calcium release and TFEB activation is not shown. Neither is the requirement for calcineurin.

4\) Although the synergistic effect of BDQ with PZA seems to approach 1 log (\~10% survival) killing of *M. tuberculosis*, the effect size of BDQ alone (Figure 3F) is quite small. This raises questions of how significant these observations are to TB. This is important, since the whole setup is to find new therapeutic agents to control MDR TB.

5\) The authors use BAPTA (extracellular) to eliminate calcium and test the effect of loss of TFEB activation on bacterial CFU. This is done with *S. aureus* (not TB). Also, if they really are using BAPTA, they would not be inhibiting intracellular calcium release but import from extracellular stores, changing the interpretation of the experiment.

\[Editors' note: further revisions were suggested prior to acceptance, as described below.\]

Thank you for resubmitting your work entitled \"The antibiotic bedaquiline activates host macrophage innate immune resistance to bacterial infection\" for further consideration by *eLife*. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by a Reviewing Editor and a Senior Editor.

The manuscript has been improved and the reviewers are generally enthusiastic about publication but there are some remaining issues that need to be addressed before acceptance. Please revise your manuscript to address these issues.

*Reviewer \#1:*

The revised manuscript addresses the main concerns of this reviewer. Overall, I think the data strongly indicate that the antibiotic bedaquiline (BDQ) can induce antibacterial responses by direct action on host cells. The mechanism of action of BDQ is of great importance to the TB field, and the concept that antibiotics can act (in part) by targeting the host is of even broader importance.

My only query relates to new data (Figure 7) showing that human macrophages induce nitrite, which the authors claim is derived from host NO. As far as I am aware, there has been considerable difficulty demonstrating induction of NO by human macrophages in culture. In some cases, the NO2- observed has actually been produced by the bacteria themselves (see Bussel, Zhang and Nathan, 2013). The authors may want to take this into account.

10.7554/eLife.55692.sa2

Author response

\[Editors' note: the authors resubmitted a revised version of the paper for consideration. What follows is the authors' response to the first round of review.\]

> \[...\]
>
> 1\) A major concern is that the manuscript does not cleanly demonstrate that the effects of BDQ observed on MTB growing in cells is in fact due to the effects of BDQ on the host cells vs. effects of BDQ on MTB. The use of a BDQ resistant mutant is a nice attempt to address this concern, but it is not entirely satisfactory. First, the data shown in Figure 1---figure supplement 2C demonstrate that BDQ (5µg/mL) does appear to have an effect on growth of the resistant mutant. Second, even if growth of the bacteria is unimpeded in broth, the antibiotic may still have an effect on the bacteria in cells. Even a minor effect on MTB (e.g., lysis of a few bacteria) might have a large effect on the host response. Unless this central concern can be satisfactorily addressed (which we fear it may not be) then we do not feel the paper would be a strong candidate for eLife.

We thank the reviewer 2 for raising this point, acknowledging that this may be due to problems in our writing. Our main goal was to show that BDQ can activate macrophages, making them resistant to any bacterial infections, and not just to infection with MTB. In the revised manuscript, we present new data, which clearly show that BDQ induces bactericidal functions by directly targeting the host.

The first question is to what extent is the MTB mutant resistant to BDQ (BDQr-MTB). The MIC~99~ of the mutant is 36 µg/mL, which is much higher than the concentration that we used. In our paper, BDQ is used at a maximum concentration of 5 µg/mL during 48 hours and 1 µg/mL during 5 days. At these concentrations, we never observed bacterial killing nor decrease of bacterial growth in liquid medium (Figure 1---figure supplement 2B). We also showed that the bacillary load of resistant MTB inside macrophages is the same in untreated cells as in cells after 18 hours of BDQ treatment (the time point chosen for the RNAseq experiment). In contrast, in the same experiment using BDQ-susceptible MTB there is a 70% decrease in the bacillary load (Figure 1---figure supplement 2C).

We agree that BDQ might kill a few intracellular bacteria (even if we did not detect any changes by CFUs), but it is very unlikely that this effect could explain the macrophage resistance to bacterial infection. First, the effect of BDQ can also be inhibited by 3-MA and BAF, whereas these two autophagy inhibitors have no effect on untreated cells (Figure 6F). These results suggest a host-targeted effect of BDQ. The regulation of the lysosomal pathway by BDQ is also observed in uninfected macrophages and in cells stimulated with heat-inactivated MTB or with TLR agonists such as LPS and Pam3CSK4 (Figure 3---figure supplement 2). Such changes were not observed in cells treated with the first line anti-TB drugs ethambutol (EMB), isoniazid (INH), pyrazinamide (PZA) and rifampicin (RIF) (new transcriptome analysis presented in Figure 5A-C and Figure 5---figure supplement 2, and LysoTracker staining analyzed by flow cytometry Figure 5D).

If the lysis of a few bacteria by BDQ induced macrophage activation, then we would expect a greater response when the cells are stimulated by heat-killed bacteria or drug-susceptible MTB than with BDQr-MTB. Again, as shown in Figure 3---figure supplement 2, we did not observe any differences in the intensity of LysoTracker staining. Similar results have also been obtained when comparing the expression level of lysosomal genes. Overall, our results strongly argue for a host-dependent effect of BDQ.

> 2\) Another major concern relates to the presentation of the RNAseq data in Figure 1A-B and Figure supplement 3A-B. Figure 1AB shows the effect of BDQ on MTB-infected macrophages, whereas Figure supplement 3A-B shows the effect of BDQ on uninfected macrophages. If BDQ acts on host cells independent of an effect on bacteria, then we would expect similar genes to be induced in both conditions. However, the data are presented only at the level of GO-term annotations. We require gene-level expression data comparing gene induction in all four conditions (+/- BDQ and +/- MTB) in a single analysis so that we can assess whether in fact the effects of BDQ are similar +/- MTB. It may well be that MTB modulates the host response to BDQ, e.g., via activation of TLRs. In such a case, it might be useful to compare the response of cells infected with live TB +/- BDQ with the response to cells treated with TLR agonists or killed bacteria +/- BDQ. If, however, the main effects of BDQ on host gene expression only appear to occur in conjunction with infection with live MTB, then we would be concerned that the effects of BDQ are via their effects on MTB and not direct host-directed effects.

Here we present new analysis, comparing gene expression level in all four conditions (+/- BDQ and +/- MTB). Upon BDQ treatment, 127 and 1043 genes, respectively, were differentially expressed in naïve cells and in MTB-infected macrophages, and the expression of 452 genes was modulated in both conditions. It is not surprising that the expression of more genes was affected in MTB-infected cells as MTB infection induces extensive remodeling of the transcriptome (Barreiro et al., 2012; Tailleux et al., 2008). We then classified all these genes by performing gene-set enrichment analysis. We showed that the expression of 70% of the lysosomal gene differentially expressed in MTB-infected macrophages, were also up-regulated in naïve cells upon BDQ treatment. These results are now included in Figure 1D and Figure 3A. We also performed additional experiments to determine whether the effects of BDQ on host gene expression were dependent of infection with live MTB. Briefly, cells were untreated or stimulated with LPS (TLR4 agonist), Pam3CSK4 (TLR1/2 agonist), heat-killed bacteria, drug-susceptible MTB or BDQr-MTB, and treated with BDQ. After 18 hours, RNA was collected and we performed RT-qPCR on a panel of lysosomal genes. We also analyzed the intensity of the LysoTracker staining using flow cytometry (*Figure 3---figure supplement 2*). Our results clearly show that the main effects on lysosome biogenesis/activation occurred with BDQ treatment and were not exclusively seen after infection with live MTB.

> 3\) Another major concern is that there is no direct evidence that the apparent effects of BDQ on MTB growing in cells is due to induction of TFEB. This should be shown with TFEB mutant cells. These cells could also be used to show that the induction of lysosomal-related genes and increased lysotracker staining by BDQ is due to TFEB activation.

Using siRNA-mediated gene silencing (Troegeler et al., 2014), we inactivated the expression of TFEB in macrophages and confirmed its major role in the resistance to bacterial infection upon BDQ treatment. We also present a chromatin immunoprecipitation assay with anti-TFEB antibody. As suggested by reviewers 1 and 3, we showed that TFEB activation is required for (i) the increased LysoTracker staining (Figure 9G), (ii) the induction of a panel of lysosomal-related genes (Figure 9H), and (iii) a better control of *S. aureus* and MTB infection upon BDQ treatment (Figure 9I-J).

> 4\) As raised by reviewer 2, it is imperative to show that the synergy between BDQ and PZA on the BDQ-resistant mutant does not occur in broth.

We performed the suggested experiment. As shown in Figure 4B, we found no synergy between BDQ and PZA on the BDQ-resistant mutant cultivated in Middlebrook 7H9 liquid medium.

> \- A MIC for BDQ on the resistant mutant should be reported.

This has been added in the revised version. We determined the MIC~99~ (defined as the concentration required to prevent 99% growth) of both wild-type and BDQ-resistant MTB by the colorimetric resazurin microtiter assay (Palomino et al., 2002). The MIC for susceptible MTB was 0.07 µg/mL, a value similar to previously published studies (Andries et al., 2005), and the MIC~99~ of the BDQr-MTB was 36 µg/mL.

> \- Figure 1---figure supplement 2B is missing information about what concentration of BDQ was used.

This has been corrected in the revised version.

> \- Reviewer 2 raised a number of questions about the data in Figure 1---figure supplement 2C that should be addressed.

We thank the reviewer for the points raised about the experiment displayed in Figure 1---figure supplement 2C, which could question the virulence of the both wild-type and BDQ-resistant MTB. In the former version of our paper, we only quantified the number of intracellular bacteria, excluding the extracellular bacilli released from necrotic cells. This gave the wrong impression that bacteria do not multiply within macrophages. In the revised manuscript we provide new data from CFUs and confocal microscopy showing that wild-type and BDQ-resistant MTB are both virulent and replicate inside macrophages (Figure supplement 2C-E).

> \- As raised by reviewer 3, the proposed mechanism connecting BDQ to calcium and TFEB activation is only weakly supported by data. The authors should consider toning down their conclusions related to this part of the paper.

The calcium chelation experiments were performed with BAPTA-AM, not BAPTA (please see our comments to reviewer \#3). We would like to apologize for this error and have corrected it in the revised manuscript.

> Reviewer \#1:
>
> \[...\]
>
> 1\) Transcriptional profiling is performed on both MTB-infected and in uninfected cells. It is claimed that the effects of BDQ are \"similar\" in both situations. However, the way the data are presented makes it hard to see how similar or different the effects of BDQ are +/- MTB. Could the authors present a heat-map (indicating key genes, particularly the lysosomal signature) with all four conditions (+/- MTB, +/- BDQ) in a single analysis/panel? If there are significant differences, it might be relevant to comment on these.

We thank the reviewer for his positive feedback and for fair suggestions. In the revised manuscript, we present a new analysis (Figure 1). MTB infection induces important transcriptome remodeling (7,093 genes were differentially expressed upon infection with BDQr-MTB) so it is not surprising that the expression of more genes were altered after BDQ treatment of MTB-infected macrophages than uninfected macrophages. In the new version, we comment on these and present functional annotation clustering of the corresponding genes (Figure 1A-B). In the former version of our manuscript, we wrote that "We observed similar results with uninfected Mφs-treated with BDQ \[...\] indicating that the effect of BDQ is not dependent on MTB infection". We were principally referring here to the lysosome pathway and lipid metabolism. 452 genes were differentially expressed in both uninfected- and MTB infected cells. Classification of these genes using gene-set enrichment analysis shows an enrichment for genes associated with lysosome (Figure 1C-D). The expression of 70% of the lysosomal genes found to be differentially expressed in BDQr-MTB-infected cells, were also regulated in naïve cells upon BDQ treatment (Figure 3A). As suggested, we have added a first heat-map of the genes most up- and down-regulated in naïve- and MTB-infected cells treated with BDQ (Figure 1D), and a second heat-map focusing on the expression of lysosomal genes in all four conditions +/- MTB +/- BDQ (Figure 3A).

> 2\) A weakness of the manuscript is that the direct host-cell target of BDQ is not identified. Thus, the mechanism leading to TFEB induction is unclear. However, I tend to feel that identification of the target of BDQ is beyond what could be reasonably asked of this study. However, perhaps the authors could at least briefly discuss what the host cell target of BDQ might be and acknowledge that they have not identified it. In addition, the evidence that the effects of BDQ require TFEB is only indirect. It would thus be desirable, if feasible, for the authors to show, e.g., with TFEB knock out cells, that the effects of BDQ on lysosome-related gene induction does require TFEB.

Finding the direct host-cell target of BDQ would have been a major breakthrough, but unfortunately, we were unable to identify the target. However, it is possible that BDQ could modulate the host response by interfering with ion homeostasis inside the lysosome. Greenwood et al., recently showed that BDQ accumulated primarily in host cell lipid droplets (Greenwood et al., 2019). It is tempting to speculate that these droplets are actually lysosomes. Due to its high hydrophobicity, BDQ might accumulate in lysosomal membranes and thereby change the transmembrane ion permeability. In agreement with this hypothesis, it has been shown that BDQ can accumulate at the lipid membrane of liposomes and act as a H^+^/K^+^ ionophore (Hards et al., 2018). The ensuing lysosomal stress could then facilitate the dissociation of mTOR from the lysosomal membrane (Plescher et al., 2015) and the activation of TFEB. Interestingly, BDQ increases the expression of mucolipin 1 gene (*mcoln1*, Figure 3A and Figure 3---figure supplement 2A). Recently, Medina et al. showed that lysosomal Ca^2+^ is released through MCOLN1 and activates calcineurin, which binds and dephosphorylates TFEB (Medina et al., 2015) (Medina et al., 2015). These two hypotheses are now mentioned in the Discussion section of our paper.

In the revised manuscript, we present additional experiments, including silencing of TFEB expression using siRNA and chromatin purification with anti-TFEB antibody. The results show that the effects of BDQ on the induction of genes linked to lysosomes indeed require TFEB (Figure 9 and Figure 9---figure supplement 1).

> Reviewer \#2:
>
> \[...\]
>
> 1\) It seems likely to me that the transcriptional (Figure 1) and functional effects (Figures 2- of BDQ on infected macrophages is due to indirect effects on bacterial physiology. The use of the BDQ-resistant mutant is an important experiment, but I have doubts that the concentration used for the macrophage infection studies (5µg/mL) does not have any effect on the bacteria. This concentration apparently inhibits the growth of the resistant mutant Figure S1C inside macrophages, and this could be due to either activation of antimicrobial host effects or partial inhibition of bacterial growth. It is not clear what effects this concentration has on the bacteria, the mutant was selected on 0.3 µg/mL BDQ, and I could not find an MIC stated in the manuscript. The growth curve of bacteria grown in axenic culture +/- BDQ (panel B) is missing any information about the concentration of BDQ used, and there is no direct comparison of the growth kinetics between wild-type and mutant bacteria at 5 µg/mL. Moreover, the assumption is that treatment with 5µg/mL of BDQ doesn\'t change the bacteria at all, and thus any differences must be due to host modulation, yet I think there are multiple reasons to doubt this.

We thank the reviewer 2 for raising the question to what extent is the MTB mutant resistant to BDQ (BDQr-MTB). We first determined the MIC~99~ (defined as the concentration required to prevent 99% growth) of both wild-type- and BDQ-resistant MTB by the colorimetric resazurin microtiter assay (Palomino et al., 2002). The MIC for susceptible MTB was 0.07 µg/mL, a value similar to previously published study (Andries et al., 2005), while the MIC~99~ of the BDQr-MTB was 36 µg/mL. The CFUs and the growth curves of both WT and BDQr-MTB, with and without different concentrations of BDQ are now included in the manuscript (Figure 1---figure supplement 2B-C). Unlike drug-susceptible MTB, BDQrMTB continues to growth in the presence of 5 µg/mL BDQ, and we observed a slight decrease in growth only after 7 days of treatment. In our paper, BDQ is used at a maximum concentration of 5 µg/mL during 48 h and 1 µg/mL during 5 days. At these concentrations, we observed neither bacterial killing nor a decrease of bacterial growth in liquid medium (Figure 1---Figure supplement 2B-C). We also show that the bacillary load of resistant MTB inside macrophages is the same in untreated cells as in cells after 18 h of BDQ treatment (the time point chosen for the RNAseq experiment). In contrast, in the same experiment using BDQ-susceptible MTB there is a 70% decrease in the bacillary load (Figure 1---figure supplement 2C).

We agree that we cannot exclude the possibility that BDQ may affect the metabolism of BDQr-MTB, but it seems unlikely that this would explain the macrophage resistance to bacterial infection upon BDQ treatment. First, the effect of BDQ can be inhibited by 3-MA and BAF, whereas these two autophagy inhibitors have no effect on untreated cells (Figure 6F). These results suggest a host-targeted effect of BDQ. The regulation of the lysosomal pathway by BDQ seen in MTB infected macrophages was also observed in naïve macrophages and in cells stimulated with heat-inactivated MTB or with TLR agonists LPS and Pam3CSK4 (Figure 3---figure supplement 2). These changes were not observed in cells treated with the first line anti-TB drugs ethambutol (EMB), isoniazid (INH), pyrazinamide (PZA) and rifampin (RIF) (new transcriptome analysis presented in Figure 5A-B-C and Figure 6---figure supplement 2, and LysoTracker staining analyzed by flow cytometry Figure 5D).

If the lysis of a few bacteria by BDQ induces macrophage activation, we would expect a greater response when the cells are stimulated by heat-killed bacteria or drug-susceptible MTB than was observed with BDQr-MTB. Again, as shown in Figure 3---figure supplement 2B, we did not observe any differences in the intensity of LysoTracker staining. Similar results have also been obtained when comparing the expression level of lysosomal genes.

Overall, our results strongly argue for a host-dependent effect of BDQ.

> 2\) There are a number of other worrisome details about the experiment displayed in Figure S1C. First, it is curious that neither the wild-type nor resistant bacteria grew very well between the 18hour and 5day time points in the absence of BDQ. It appears they double at best, but much more would be expected. Second, the BDQ-resistant mutant didn\'t grow at all over this 4+ day time course in the presence of 5µg/mL BDQ. It seems unlikely to me that this effects of BDQ are solely due to host activation. Third, why are the CFU levels of the mutant bacteria so much higher than the wild-type at 18hours?

We thank the reviewer for the points raised about the experiment displayed in the former Figure 1---figure supplement 1C, which could question the virulence of both wild-type and BDQ-resistant MTB. In the former version of our paper, we only quantified the number of intracellular bacteria, excluding the extracellular bacillus released from necrotic cells. This gave the erroneous impression that the bacteria did not multiply inside macrophages. In the revised manuscript, we provide new data from CFUs and confocal microscopy showing that wild-type and BDQ-resistant MTB are virulent and replicate within macrophages.

> 3\) It seems important to demonstrate in all of their bacterial infections, including Figure 4, that the macrophage monolayers are intact and of equal density amongst all the treatments. Indeed, while the authors test the effects of BDQ on macrophage viability in the absence of bacteria, it seems important to assess its effect during the heightened inflammatory response during infection.

The viability of naïve and infected macrophages, treated with the different molecules used in this study, were assessed using the MTT or LDH assay. As shown in Figure 1---figure supplement 1, we noted no toxicity of the compounds. As expected, we only observe a decrease in cell viability of MTB-infected macrophages after 48 h of infection.

> 4\) I believe that the results with the host effects of BDQ would be more conclusive if they could show that treatment with different antibiotics gives rise to different results.

In the initial version of our manuscript, we only tested whether first-line anti-TB drugs could induce an increase in LysoTracker staining. We agree that further analysis of the effects of other drugs on the macrophages response would be more conclusive. We therefore used RNAseq to characterize the genome-wide gene expression profiles of naïve cells and cells stimulated with heat-killed MTB, and treated with ethambutol (EMB), isoniazid (INH), pyrazinamide (PZA) or rifampicin (RIF). We chose heat-killed MTB instead of drug-resistant MTB for the following reasons:

\(i\) We cannot work with multidrug-resistant MTB in our BSL3 facility, and the generation of resistant mutants for each antibiotic would not have been reasonable in terms of time to resubmit a revised version of our manuscript.

\(ii\) Most of the genes upon that were differentially expressed after MTB infection are also modulated upon stimulation with heat-killed MTB ((Pacis et al., 2015) and Figure 6---figure supplement 1).

\(iii\) The activation of the lysosomal pathway by BDQ does not require infection with live MTB, as most of the lysosomal genes are also differentially expressed in naïve cells exposed to BDQ (Figure 3A).

Following treatment, only RIF and PZA significantly modulate gene expression in macrophages. 556 and 752 genes were differentially expressed in cells stimulated with heat-killed bacteria and exposed to PZA and RIF respectively (Figure 5A). We classified these genes by performing gene-set enrichment analysis and confirmed that the genes in the lysosomal pathway were not induced upon RIF or PZA treatment. The expression of only 2 genes belonging to this pathway was upregulated by RIF, and only one by PZA, compared to 46 whose expression was modulated by BDQ (FDR\<5%, absLogFC\>0.1, Figure 5B-C and Figure 5---figure supplement 2).

> 5\) The authors also perform treatment of macrophages with BDQ in the absence of infection, and claim that similar pathways are activated, inferring that these effects are independent of the presence of bacteria. Unfortunately, these comparisons were evaluated at the level of GO pathway annotation, and I believe strongly that if BDQ is directly activating gene expression, perhaps via PTFB, that the comparison should be performed at the gene level, i.e. as done in Figure 2A.

In the revised manuscript, we present new data comparing the gene expression level in all four conditions (+/- BDQ and +/- MTB), and as suggested by reviewer 2, we show a heat-map with the differentially expressed genes associated with the lysosome pathway (Figure 3A). The expression of 70% of the lysosomal pathway genes, differentially expressed in MTB-infected macrophage, were also upregulated in naïve cells upon BDQ treatment.

We also performed additional experiments to demonstrate that the effects of BDQ on host gene expression were independent of infection with live MTB. Briefly, cells were untreated or stimulated with LPS (TLR4 agonist), Pam3CSK4 (TLR1/2 agonist), heat-killed bacteria, drug-susceptible MTB or BDQr-MTB, and treated with BDQ. After 18 h, RNA was collected, and RT-qPCR performed on a panel of lysosomal genes. We also analyzed the intensity of the LysoTracker staining using flow cytometry (Figure 3---figure supplement 1). The results clearly show that the effect of BDQ on lysosome biogenesis/activation is independent of MTB infection and of Toll-like receptor stimulation.

> 6\) I find the conclusion drawn from the apparent synergy btw PZA and BDQ is misleading for two reasons. First of all, given the residual sensitivity of the resistant mutant to high levels of BDQ, it seems imperative that this synergy be tested in culture. Second, given the model that BDQ activates host antimicrobial activities, I expect that BDQ would also synergize with other antibiotics besides PZA.

We tested the synergy between BDQ and PZA in culture liquid medium using increasing concentrations of PZA (from 0 to 400 µg/mL) with or without BDQ (1 µg/mL). At this BDQ concentration, the growth of BDQr-MTB is not affected by BDQ over a period of 12 days (Figure 1---figure supplement 2B) and we observed an increase of the DQ-BSA staining in macrophages (Figure 3F). We observed no synergy between BDQ and PZA in culture liquid medium, suggesting a hostdependent mechanism. We next tested whether BDQ would synergize with the other first-line anti-TB drugs in liquid culture or in BDQr-MTB-infected macrophages and found that BDQ did not potentiate the activity of INH, RIF and EMB in either case. While we cannot exclude the possibility that BDQ may have additive effects with other anti-TB drugs, as has been described (Ibrahim et al., 2007), we saw no evidence of synergism with any of the first-line agents (Figure 4---figure supplement 1).

> 7\) Much of the lysosome results in Figure 2 is complicated by the mild sensitivity of the resistant strain to BDQ. The one experiment that is interesting is the no-infection in panel G, but there is only a correlation, there is no evidence provided that this is the host effect of BDQ.

In the revised version, we add a new supplemental figure describing the lysosomal regulation in uninfected cells (Figure 3---figure supplement 1). As we mention in the text, lysosome biogenesis/activation is increased in both naïve and BDQr-MTB-infected macrophages upon BDQ treatment.

> Reviewer \#3:
>
> \[...\]
>
> 1\) The proposed mechanism of enhancement of bactericidal activity is through TFEB, but the only evidence presented is correlative (TFEB immunofluorescence showing TFEB in the nucleus). This must be directly tested using loss-of-function approaches.

To study the role of TFEB in the enhancement of bactericidal activity upon BDQ treatment in more depth, we inactivated TFEB expression in human monocyte-derived macrophages using siRNA-mediated gene silencing (Troegeler et al., 2014). After treating the cells with BDQ, we performed RTqPCR on a panel of lysosomal genes and analyzed the intensity of the LysoTracker staining using flow cytometry. In TFEB-silenced cells, BDQ does not increase LysoTracker staining (Figure 9G), nor the expression of *trpm2*, *scarb1*, *atp6v0a1* or *mcoln1* (Figure 9H). We also infected macrophages with *S. aureus* and MTB and showed that TFEB activation is required for better control of both pathogens upon BDQ treatment (Figure 9I-J). In addition, we present a chromatin immunoprecipitation assay using an anti-TFEB antibody (please see the comment below).

> 2\) Similarly, the implication from the RNAseq, LysoTracker, and TFEB IF is that TFEB upregulates the genes responsible for lysosomal biogenesis and autophagy, thus increasing bacterial clearance. The inducible recruitment of TFEB to relevant promoters must be directly tested.

We evaluated the recruitment of TFEB to the promoters of some lysosomal genes. Briefly, naïve- and heat-killed-stimulated cells treated with BDQ were lysed, and chromatin was harvested and fragmented using sonication. The chromatin was then subjected to immunoprecipitation using an antiTFEB antibody. The isolated DNA was then analyzed by RT-qPCR with primers specific for *gla* and *mcoln1* promoters. As expected, BDQ induces the recruitment of TFEB to these promoters (Figure 8---figure supplement 1).

> 3\) The mechanism connecting BDQ to calcium release and TFEB activation is not shown. Neither is the requirement for calcineurin.

Unfortunately, we were unable to identify the mechanism connecting BDQ to TFEB activation.

Greenwood et al., recently showed that BDQ accumulated primarily in host cell lipid droplets (Greenwood et al., 2019). It is tempting to speculate that these droplets are actually lysosomes. Due to its high hydrophobicity, BDQ might accumulate in lysosomal membranes and thereby change transmembrane ion permeability. In agreement with this hypothesis, it has been shown that BDQ can accumulate at the lipid membrane of liposomes and act as a H^+^/K^+^ ionophore (Hards et al., 2018). The ensuing lysosomal stress could then facilitate the dissociation of mTOR from the lysosomal membrane (Plescher et al., 2015) and the activation of TFEB. Interestingly, BDQ increases the expression of mucolipin 1 gene (*mcoln1*, Figure 3A and Figure 3---figure supplement 2A). Recently, Medina et al. showed that lysosomal Ca^2+^ is released through MCOLN1 and activates calcineurin, which binds and dephosphorylates TFEB (Medina et al., 2015). These two hypotheses are now mentioned in the Discussion section.

> 4\) Although the synergistic effect of BDQ with PZA seems to approach 1 log (\~10% survival) killing of M. tuberculosis, the effect size of BDQ alone (Figure 3F) is quite small. This raises questions of how significant these observations are to TB. This is important, since the whole setup is to find new therapeutic agents to control MDR TB.

In the former Figure 3F, we used a low concentration of BDQ (1 µg/mL) in order to discriminate between additive and synergic effect. At higher concentration of BDQ (5 µg/mL, the concentration detected in the plasma of TB patients treated with BDQ (Andries et al., 2005)), we observed a 50% decrease in the number viable bacteria (now in Figure 6F).

> 5\) The authors use BAPTA (extracellular) to eliminate calcium and test the effect of loss of TFEB activation on bacterial CFU. This is done with *S. aureus* (not TB). Also, if they really are using BAPTA, they would not be inhibiting intracellular calcium release but import from extracellular stores, changing the interpretation of the experiment.

The calcium chelation experiments were performed with BAPTA-AM, not BAPTA. We would like to apologize for this error and have corrected it in the revised manuscript. Unlike BAPTA, which is a membrane-impermeable calcium chelator that binds extracellular calcium ions, BAPTA-AM is a cell permeable analog of BAPTA that binds calcium only after the acetoxymethyl group is removed by cytoplasmic esterases (Tymianski et al., 1994). It is highly selective for Ca^2+^ over Mg^2+^, and It is commonly used to evaluate the role of intracellular Ca^2+^ in cell signaling.

\[Editors' note: what follows is the authors' response to the second round of review.\]

> Reviewer \#1:
>
> \[...\]
>
> My only query relates to new data (Figure 7) showing that human macrophages induce nitrite, which the authors claim is derived from host NO. As far as I am aware, there has been considerable difficulty demonstrating induction of NO by human macrophages in culture. In some cases, the NO2- observed has actually been produced by the bacteria themselves (see Bussel, Zhang and Nathan, 2013). The authors may want to take this into account.

We thank the reviewer for his/her positive comments and suggestions, which have enabled us to improve our manuscript significantly. We agree the role of NO in the inhibition of *M. tuberculosis* growth is controversial in human. However, in Figure 7D, we quantified NO2- in uninfected cells upon BDQ treatment, which excludes nitric oxide produced by bacteria.

[^1]: These authors also contributed equally to this work.

[^2]: These authors also contributed equally to this work.
